Testhyperlink123: Difference between revisions
Jump to navigation
Jump to search
Guptareeya53 (talk | contribs) No edit summary |
Guptareeya53 (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00031MO G00031MO] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00031MO G00031MO] <br> | ||
'''term_in_sentence''' : Tn, sTn, and T antigen neo- or over-expression occurs in many types of cancer including gastric, colon, breast, lung, esophageal, prostate, and endometrial cancer.[PMID:27679419] <br> | '''term_in_sentence''' : Tn, sTn, and T antigen neo- or over-expression occurs in many types of cancer including gastric, colon, breast, lung, esophageal, prostate, and endometrial cancer.[PMID:27679419] <br> | ||
'''publication''' : 723127|[https://pubmed.ncbi.nlm.nih.gov/19505650 19505650]|[https://pubmed.ncbi.nlm.nih.gov/31527246 31527246]|[https://pubmed.ncbi.nlm.nih.gov/28113048 28113048]|[https://pubmed.ncbi.nlm.nih.gov/25868857 25868857]|[https://pubmed.ncbi.nlm.nih.gov/26731525 26731525]|[https://pubmed.ncbi.nlm.nih.gov/22994493 22994493]|[https://pubmed.ncbi.nlm.nih.gov/3849428 3849428]|[https://pubmed.ncbi.nlm.nih.gov/25589241 25589241]| | '''publication''' :[https://pubmed.ncbi.nlm.nih.gov/723127 723127]|[https://pubmed.ncbi.nlm.nih.gov/19505650 19505650]|[https://pubmed.ncbi.nlm.nih.gov/31527246 31527246]|[https://pubmed.ncbi.nlm.nih.gov/28113048 28113048]|[https://pubmed.ncbi.nlm.nih.gov/25868857 25868857]|[https://pubmed.ncbi.nlm.nih.gov/26731525 26731525]|[https://pubmed.ncbi.nlm.nih.gov/22994493 22994493]|[https://pubmed.ncbi.nlm.nih.gov/3849428 3849428]|[https://pubmed.ncbi.nlm.nih.gov/25589241 25589241]|[https://pubmed.ncbi.nlm.nih.gov/12709866 12709866]|[https://pubmed.ncbi.nlm.nih.gov/26615524 26615524]|[https://pubmed.ncbi.nlm.nih.gov/26136575 26136575]|[https://pubmed.ncbi.nlm.nih.gov/19671663 19671663]|[https://pubmed.ncbi.nlm.nih.gov/18551603 18551603]|[https://pubmed.ncbi.nlm.nih.gov/11160729 11160729]|[https://pubmed.ncbi.nlm.nih.gov/22261839 22261839]|[https://pubmed.ncbi.nlm.nih.gov/30758913 30758913]|[https://pubmed.ncbi.nlm.nih.gov/25681708 25681708]|[https://pubmed.ncbi.nlm.nih.gov/29113555 29113555]|[https://pubmed.ncbi.nlm.nih.gov/24998850 24998850]|[https://pubmed.ncbi.nlm.nih.gov/1654819 1654819]|[https://pubmed.ncbi.nlm.nih.gov/28039910 28039910]|[https://pubmed.ncbi.nlm.nih.gov/29206210 29206210]|[https://pubmed.ncbi.nlm.nih.gov/32404521 32404521]|[https://pubmed.ncbi.nlm.nih.gov/10555041 10555041]|[https://pubmed.ncbi.nlm.nih.gov/26517398 26517398]|[https://pubmed.ncbi.nlm.nih.gov/2446015 2446015]|[https://pubmed.ncbi.nlm.nih.gov/2998768 2998768]|[https://pubmed.ncbi.nlm.nih.gov/3026642 3026642]|[https://pubmed.ncbi.nlm.nih.gov/18812503 18812503]|[https://pubmed.ncbi.nlm.nih.gov/6092664 6092664]|[https://pubmed.ncbi.nlm.nih.gov/2153691 2153691]|[https://pubmed.ncbi.nlm.nih.gov/8709258 8709258]|[https://pubmed.ncbi.nlm.nih.gov/3009889 3009889]|[https://pubmed.ncbi.nlm.nih.gov/15109748 15109748]| [https://pubmed.ncbi.nlm.nih.gov/12709866 12709866]|[https://pubmed.ncbi.nlm.nih.gov/31787742 31787742]|[https://pubmed.ncbi.nlm.nih.gov/27433780 27433780]|[https://pubmed.ncbi.nlm.nih.gov/26017382 26017382]|[https://pubmed.ncbi.nlm.nih.gov/24048785 24048785]|[https://pubmed.ncbi.nlm.nih.gov/26735515 26735515]|[https://pubmed.ncbi.nlm.nih.gov/9224657 9224657]|[https://pubmed.ncbi.nlm.nih.gov/26061652 26061652]|[https://pubmed.ncbi.nlm.nih.gov/29343574 29343574]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/25681708 25681708] [https://pubmed.ncbi.nlm.nih.gov/25681708 25681708]]|[https://pubmed.ncbi.nlm.nih.gov/23805194 23805194]|[https://pubmed.ncbi.nlm.nih.gov/26751495 26751495]|[https://pubmed.ncbi.nlm.nih.gov/22023388 22023388]|[https://pubmed.ncbi.nlm.nih.gov/15381338 15381338]|[https://pubmed.ncbi.nlm.nih.gov/8249277 8249277]|[https://pubmed.ncbi.nlm.nih.gov/3023660 3023660]|[https://pubmed.ncbi.nlm.nih.gov/25866902 25866902] <br> | ||
'''definition''' : An amino disaccharide composed of D-galactose and N-acetyl-α-D-galactosaminyl residues in β-(1→3) linkage.[CHEBI:61820] <br> | '''definition''' : An amino disaccharide composed of D-galactose and N-acetyl-α-D-galactosaminyl residues in β-(1→3) linkage.[CHEBI:61820] <br> | ||
'''term_xref''' : GTC:G00031MO|GlycoEpitope:EP0020|CID: | '''term_xref''' : GTC:G00031MO|GlycoEpitope:EP0020|CID:5288347|CHEBI:61820|GlycoMotif:GGM.000009<br> | ||
'''synonyms''' : TF antigen <br> | '''synonyms''' : TF antigen <br> | ||
'''function''' : accumulation Lipoprotein(a) or LDL within arterial walls in atherogenesis [GlycoEpitope:EP0020]|cancer progression (increase interaction/communication of the cells)[GlycoEpitope:EP0020]|T antigen expression in RMA lymphoma cells leads to a reduced growth of the tumor[GlycoEpitope:EP0020]|correlation with elevated Golgi pH in cancer cell (breast, colorectal cancer cells)[GlycoEpitope:EP0020]|T antigen on apical surfaces of corneal epithelial cells provide protection against rose bengal penetrance.[GlycoEpitope:EP0020]|reduction of a flexibility of the glycosidic bond and thereby favour certain glycan conformation[GlycoEpitope:EP0020]|T antigen is a target for NK cell-mediated lysis[GlycoEpitope:EP0020]|inverse relationship between T antigen expression and VWF plasma levels[GlycoEpitope:EP0020] <br> | '''function''' : accumulation Lipoprotein(a) or LDL within arterial walls in atherogenesis [GlycoEpitope:EP0020]|cancer progression (increase interaction/communication of the cells)[GlycoEpitope:EP0020]|T antigen expression in RMA lymphoma cells leads to a reduced growth of the tumor[GlycoEpitope:EP0020]|correlation with elevated Golgi pH in cancer cell (breast, colorectal cancer cells)[GlycoEpitope:EP0020]|T antigen on apical surfaces of corneal epithelial cells provide protection against rose bengal penetrance.[GlycoEpitope:EP0020]|reduction of a flexibility of the glycosidic bond and thereby favour certain glycan conformation[GlycoEpitope:EP0020]|T antigen is a target for NK cell-mediated lysis[GlycoEpitope:EP0020]|inverse relationship between T antigen expression and VWF plasma levels[GlycoEpitope:EP0020] <br> | ||
| Line 21: | Line 21: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : In contrast, myeloma IgE showed a higher abundance of triantennary and tetraantennary glycan structures and a low abundance of species with a bisecting N-acetylglucosamine.[PMID:[https://pubmed.ncbi.nlm.nih.gov/24308486 24308486]] <br> | '''term_in_sentence''' : In contrast, myeloma IgE showed a higher abundance of triantennary and tetraantennary glycan structures and a low abundance of species with a bisecting N-acetylglucosamine.[PMID:[https://pubmed.ncbi.nlm.nih.gov/24308486 24308486]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24308486 24308486]|[https://pubmed.ncbi.nlm.nih.gov/17951374 17951374]|[https://pubmed.ncbi.nlm.nih.gov/28880909 28880909]|[https://pubmed.ncbi.nlm.nih.gov/9177699 9177699]|[https://pubmed.ncbi.nlm.nih.gov/9760189 9760189]|[https://pubmed.ncbi.nlm.nih.gov/12322961 12322961]|[https://pubmed.ncbi.nlm.nih.gov/20129637 20129637]|[https://pubmed.ncbi.nlm.nih.gov/2492275 2492275]|[https://pubmed.ncbi.nlm.nih.gov/3402460 3402460]|[https://pubmed.ncbi.nlm.nih.gov/2361735 2361735]|[https://pubmed.ncbi.nlm.nih.gov/6525453 6525453]|[https://pubmed.ncbi.nlm.nih.gov/27730440 27730440]|[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/25365149 25365149]|[https://pubmed.ncbi.nlm.nih.gov/9751793 9751793]|[https://pubmed.ncbi.nlm.nih.gov/29875690 29875690]|[https://pubmed.ncbi.nlm.nih.gov/29479898 29479898]|[https://pubmed.ncbi.nlm.nih.gov/9134426 9134426]|[https://pubmed.ncbi.nlm.nih.gov/30943309 30943309]|[https://pubmed.ncbi.nlm.nih.gov/3546284 3546284]|[https://pubmed.ncbi.nlm.nih.gov/29888905 29888905]|[https://pubmed.ncbi.nlm.nih.gov/30624066 30624066]|[https://pubmed.ncbi.nlm.nih.gov/30537828 30537828]|[https://pubmed.ncbi.nlm.nih.gov/31110965 31110965]|[https://pubmed.ncbi.nlm.nih.gov/29311294 29311294]|[https://pubmed.ncbi.nlm.nih.gov/12852965 12852965]|[https://pubmed.ncbi.nlm.nih.gov/3015940 3015940]|[https://pubmed.ncbi.nlm.nih.gov/1907570 1907570]|[https://pubmed.ncbi.nlm.nih.gov/29137999 29137999]|[https://pubmed.ncbi.nlm.nih.gov/29359131 29359131]|[https://pubmed.ncbi.nlm.nih.gov/29858715 29858715]|[https://pubmed.ncbi.nlm.nih.gov/30295034 30295034]|[https://pubmed.ncbi.nlm.nih.gov/31829566 31829566]|[https://pubmed.ncbi.nlm.nih.gov/8381405 8381405]|[https://pubmed.ncbi.nlm.nih.gov/26929217 26929217]|[https://pubmed.ncbi.nlm.nih.gov/20662591 20662591]|[https://pubmed.ncbi.nlm.nih.gov/30612270 30612270]|[https://pubmed.ncbi.nlm.nih.gov/3089784 3089784]|[https://pubmed.ncbi.nlm.nih.gov/28186213 28186213]|[https://pubmed.ncbi.nlm.nih.gov/3427034 3427034]|[https://pubmed.ncbi.nlm.nih.gov/26763099 26763099]|[https://pubmed.ncbi.nlm.nih.gov/27354006 27354006]|[https://pubmed.ncbi.nlm.nih.gov/24991291 24991291]|[https://pubmed.ncbi.nlm.nih.gov/7496138 7496138]|[https://pubmed.ncbi.nlm.nih.gov/1940447 1940447]|[https://pubmed.ncbi.nlm.nih.gov/11114588 11114588]|[https://pubmed.ncbi.nlm.nih.gov/29031301 29031301]|[https://pubmed.ncbi.nlm.nih.gov/9448855 9448855]|[https://pubmed.ncbi.nlm.nih.gov/3979385 3979385]|[https://pubmed.ncbi.nlm.nih.gov/27722599 27722599]|[https://pubmed.ncbi.nlm.nih.gov/31126011 31126011]|[https://pubmed.ncbi.nlm.nih.gov/28002670 28002670]|[https://pubmed.ncbi.nlm.nih.gov/28991403 28991403]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24308486 24308486]|[https://pubmed.ncbi.nlm.nih.gov/17951374 17951374]|[https://pubmed.ncbi.nlm.nih.gov/28880909 28880909]|[https://pubmed.ncbi.nlm.nih.gov/9177699 9177699]|[https://pubmed.ncbi.nlm.nih.gov/9760189 9760189]|[https://pubmed.ncbi.nlm.nih.gov/12322961 12322961]|[https://pubmed.ncbi.nlm.nih.gov/20129637 20129637]|[https://pubmed.ncbi.nlm.nih.gov/2492275 2492275]|[https://pubmed.ncbi.nlm.nih.gov/3402460 3402460]|[https://pubmed.ncbi.nlm.nih.gov/2361735 2361735]|[https://pubmed.ncbi.nlm.nih.gov/6525453 6525453]|[https://pubmed.ncbi.nlm.nih.gov/27730440 27730440]|[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/25365149 25365149]|[https://pubmed.ncbi.nlm.nih.gov/9751793 9751793]|[https://pubmed.ncbi.nlm.nih.gov/29875690 29875690]|[https://pubmed.ncbi.nlm.nih.gov/29479898 29479898]|[https://pubmed.ncbi.nlm.nih.gov/9134426 9134426]|[https://pubmed.ncbi.nlm.nih.gov/30943309 30943309]|[https://pubmed.ncbi.nlm.nih.gov/3546284 3546284]|[https://pubmed.ncbi.nlm.nih.gov/29888905 29888905]|[https://pubmed.ncbi.nlm.nih.gov/30624066 30624066]|[https://pubmed.ncbi.nlm.nih.gov/30537828 30537828]|[https://pubmed.ncbi.nlm.nih.gov/31110965 31110965]|[https://pubmed.ncbi.nlm.nih.gov/29311294 29311294]|[https://pubmed.ncbi.nlm.nih.gov/12852965 12852965]|[https://pubmed.ncbi.nlm.nih.gov/3015940 3015940]|[https://pubmed.ncbi.nlm.nih.gov/1907570 1907570]|[https://pubmed.ncbi.nlm.nih.gov/29137999 29137999]|[https://pubmed.ncbi.nlm.nih.gov/29359131 29359131]|[https://pubmed.ncbi.nlm.nih.gov/29858715 29858715]|[https://pubmed.ncbi.nlm.nih.gov/30295034 30295034]|[https://pubmed.ncbi.nlm.nih.gov/31829566 31829566]|[https://pubmed.ncbi.nlm.nih.gov/8381405 8381405]|[https://pubmed.ncbi.nlm.nih.gov/26929217 26929217]|[https://pubmed.ncbi.nlm.nih.gov/20662591 20662591]|[https://pubmed.ncbi.nlm.nih.gov/30612270 30612270]|[https://pubmed.ncbi.nlm.nih.gov/3089784 3089784]|[https://pubmed.ncbi.nlm.nih.gov/28186213 28186213]|[https://pubmed.ncbi.nlm.nih.gov/3427034 3427034]|[https://pubmed.ncbi.nlm.nih.gov/26763099 26763099]|[https://pubmed.ncbi.nlm.nih.gov/27354006 27354006]|[https://pubmed.ncbi.nlm.nih.gov/24991291 24991291]|[https://pubmed.ncbi.nlm.nih.gov/7496138 7496138]|[https://pubmed.ncbi.nlm.nih.gov/1940447 1940447]|[https://pubmed.ncbi.nlm.nih.gov/11114588 11114588]|[https://pubmed.ncbi.nlm.nih.gov/29031301 29031301]|[https://pubmed.ncbi.nlm.nih.gov/9448855 9448855]|[https://pubmed.ncbi.nlm.nih.gov/3979385 3979385]|[https://pubmed.ncbi.nlm.nih.gov/27722599 27722599]|[https://pubmed.ncbi.nlm.nih.gov/31126011 31126011]|[https://pubmed.ncbi.nlm.nih.gov/28002670 28002670]|[https://pubmed.ncbi.nlm.nih.gov/28991403 28991403]|[https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/15316281 15316281] [https://pubmed.ncbi.nlm.nih.gov/15316281 15316281]]|[https://pubmed.ncbi.nlm.nih.gov/25154914 25154914]|[https://pubmed.ncbi.nlm.nih.gov/22490318 22490318]|[https://pubmed.ncbi.nlm.nih.gov/22430811 22430811]|[https://pubmed.ncbi.nlm.nih.gov/1463783 1463783]|[https://pubmed.ncbi.nlm.nih.gov/18803208 18803208]|[https://pubmed.ncbi.nlm.nih.gov/7881173 7881173]|[https://pubmed.ncbi.nlm.nih.gov/7697655 7697655]|[https://pubmed.ncbi.nlm.nih.gov/7240157 7240157]|[https://pubmed.ncbi.nlm.nih.gov/1768292 1768292] <br> | ||
'''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br> | '''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
| Line 35: | Line 35: | ||
'''glycan_dictionary_accession''' : GSD000165 <br> | '''glycan_dictionary_accession''' : GSD000165 <br> | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : A variety of high-mannose structures , as well as bi-, tri-, and tetraantennary complex-type carbohydrate , has been found, in relative amounts of 1-25% of the total oligosaccharides.[PMID: | '''term_in_sentence''' : A variety of high-mannose structures , as well as bi-, tri-, and tetraantennary complex-type carbohydrate , has been found, in relative amounts of 1-25% of the total oligosaccharides.[PMID: [https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]|[https://pubmed.ncbi.nlm.nih.gov/8251489 8251489]|[https://pubmed.ncbi.nlm.nih.gov/8274017 8274017]|[https://pubmed.ncbi.nlm.nih.gov/1899031 1899031]| [https://pubmed.ncbi.nlm.nih.gov/6317691 6317691]|[https://pubmed.ncbi.nlm.nih.gov/23668542 23668542]| [https://pubmed.ncbi.nlm.nih.gov/6088518 6088518]|[https://pubmed.ncbi.nlm.nih.gov/21495009 21495009]|[https://pubmed.ncbi.nlm.nih.gov/1457971 1457971]|[https://pubmed.ncbi.nlm.nih.gov/1783599 1783599]|[https://pubmed.ncbi.nlm.nih.gov/10988252 10988252]|[https://pubmed.ncbi.nlm.nih.gov/11425798 11425798]|[https://pubmed.ncbi.nlm.nih.gov/7522229 7522229]|[https://pubmed.ncbi.nlm.nih.gov/2574992 2574992]|[https://pubmed.ncbi.nlm.nih.gov/3730425 3730425]|[https://pubmed.ncbi.nlm.nih.gov/10200178 10200178]|[https://pubmed.ncbi.nlm.nih.gov/2939068 2939068]|[https://pubmed.ncbi.nlm.nih.gov/21584695 21584695]| [https://pubmed.ncbi.nlm.nih.gov/7524670 7524670]|[https://pubmed.ncbi.nlm.nih.gov/7682847 7682847]|[https://pubmed.ncbi.nlm.nih.gov/2930192 2930192]|[https://pubmed.ncbi.nlm.nih.gov/1726466 1726466]|[https://pubmed.ncbi.nlm.nih.gov/9881746 9881746]|[https://pubmed.ncbi.nlm.nih.gov/11068879 11068879]|[https://pubmed.ncbi.nlm.nih.gov/6704968 6704968]|[https://pubmed.ncbi.nlm.nih.gov/2302846 2302846]| [https://pubmed.ncbi.nlm.nih.gov/24032650 24032650]|[https://pubmed.ncbi.nlm.nih.gov/15316281 15316281]|[https://pubmed.ncbi.nlm.nih.gov/11051207 11051207]|[https://pubmed.ncbi.nlm.nih.gov/10220588 10220588]|[https://pubmed.ncbi.nlm.nih.gov/2813359 2813359]|[https://pubmed.ncbi.nlm.nih.gov/2174368 2174368]|[https://pubmed.ncbi.nlm.nih.gov/21755550 21755550]|[https://pubmed.ncbi.nlm.nih.gov/3571208 3571208]|[https://pubmed.ncbi.nlm.nih.gov/1929437 1929437]|[https://pubmed.ncbi.nlm.nih.gov/3681300 3681300]|[https://pubmed.ncbi.nlm.nih.gov/6581225 6581225]|[https://pubmed.ncbi.nlm.nih.gov/3364983 3364983]|[https://pubmed.ncbi.nlm.nih.gov/2902877 2902877]|[https://pubmed.ncbi.nlm.nih.gov/2297756 2297756]|[https://pubmed.ncbi.nlm.nih.gov/1315684 1315684]|[https://pubmed.ncbi.nlm.nih.gov/6830758 6830758]|[https://pubmed.ncbi.nlm.nih.gov/1998670 1998670] <br> | ||
'''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br> | '''definition''' : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br> | ||
'''term_xref''' : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html<br> | '''term_xref''' : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html<br> | ||
| Line 68: | Line 68: | ||
'''term_in_sentence''' : Furthermore, we confirmed that LS174T cells (Tn-positive) transfected with wild-type Cosmc, thus expressing no Tn antigen, had down-regulation of H-Ras expression and subsequent inhibition of EMT process.[PMID:30637914] <br> | '''term_in_sentence''' : Furthermore, we confirmed that LS174T cells (Tn-positive) transfected with wild-type Cosmc, thus expressing no Tn antigen, had down-regulation of H-Ras expression and subsequent inhibition of EMT process.[PMID:30637914] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27679419 27679419]|[https://pubmed.ncbi.nlm.nih.gov/31938254 31938254]|[https://pubmed.ncbi.nlm.nih.gov/30637914 30637914]|[https://pubmed.ncbi.nlm.nih.gov/24643043 24643043]|[https://pubmed.ncbi.nlm.nih.gov/31225574 31225574]|[https://pubmed.ncbi.nlm.nih.gov/21259410 21259410]|[https://pubmed.ncbi.nlm.nih.gov/31742337 31742337]|[https://pubmed.ncbi.nlm.nih.gov/28514044 28514044]|[https://pubmed.ncbi.nlm.nih.gov/33014816 33014816]|[https://pubmed.ncbi.nlm.nih.gov/28708980 28708980]|[https://pubmed.ncbi.nlm.nih.gov/27432485 27432485]|[https://pubmed.ncbi.nlm.nih.gov/33050853 33050853]|[https://pubmed.ncbi.nlm.nih.gov/26045765 26045765]|[https://pubmed.ncbi.nlm.nih.gov/27542280 27542280]|[https://pubmed.ncbi.nlm.nih.gov/24411673 24411673]|[https://pubmed.ncbi.nlm.nih.gov/27760846 27760846]|[https://pubmed.ncbi.nlm.nih.gov/30115016 30115016]|[https://pubmed.ncbi.nlm.nih.gov/1410473 1410473]|[https://pubmed.ncbi.nlm.nih.gov/29802864 29802864]|[https://pubmed.ncbi.nlm.nih.gov/29669308 29669308]|[https://pubmed.ncbi.nlm.nih.gov/29251002 29251002]|[https://pubmed.ncbi.nlm.nih.gov/32541028 32541028]|[https://pubmed.ncbi.nlm.nih.gov/31019509 31019509]|[https://pubmed.ncbi.nlm.nih.gov/1582597 1582597]|[https://pubmed.ncbi.nlm.nih.gov/2981150 2981150]|[https://pubmed.ncbi.nlm.nih.gov/10842187 10842187]|[https://pubmed.ncbi.nlm.nih.gov/29638123 29638123]|[https://pubmed.ncbi.nlm.nih.gov/22367369 22367369]|[https://pubmed.ncbi.nlm.nih.gov/10778170 10778170]|[https://pubmed.ncbi.nlm.nih.gov/1510031 1510031]|[https://pubmed.ncbi.nlm.nih.gov/19372570 19372570]|[https://pubmed.ncbi.nlm.nih.gov/20641477 20641477]|[https://pubmed.ncbi.nlm.nih.gov/16149605 16149605]|[https://pubmed.ncbi.nlm.nih.gov/15770530 15770530]|[https://pubmed.ncbi.nlm.nih.gov/27856425 27856425]|[https://pubmed.ncbi.nlm.nih.gov/23814067 23814067]|[https://pubmed.ncbi.nlm.nih.gov/28068458 28068458]|[https://pubmed.ncbi.nlm.nih.gov/32134186 32134186]|[https://pubmed.ncbi.nlm.nih.gov/8174100 8174100]|[https://pubmed.ncbi.nlm.nih.gov/10571017 10571017]|[https://pubmed.ncbi.nlm.nih.gov/27453399 27453399]|[https://pubmed.ncbi.nlm.nih.gov/1727666 1727666]|[https://pubmed.ncbi.nlm.nih.gov/23740330 23740330] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27679419 27679419]|[https://pubmed.ncbi.nlm.nih.gov/31938254 31938254]|[https://pubmed.ncbi.nlm.nih.gov/30637914 30637914]|[https://pubmed.ncbi.nlm.nih.gov/24643043 24643043]|[https://pubmed.ncbi.nlm.nih.gov/31225574 31225574]|[https://pubmed.ncbi.nlm.nih.gov/21259410 21259410]|[https://pubmed.ncbi.nlm.nih.gov/31742337 31742337]|[https://pubmed.ncbi.nlm.nih.gov/28514044 28514044]|[https://pubmed.ncbi.nlm.nih.gov/33014816 33014816]|[https://pubmed.ncbi.nlm.nih.gov/28708980 28708980]|[https://pubmed.ncbi.nlm.nih.gov/27432485 27432485]|[https://pubmed.ncbi.nlm.nih.gov/33050853 33050853]|[https://pubmed.ncbi.nlm.nih.gov/26045765 26045765]|[https://pubmed.ncbi.nlm.nih.gov/27542280 27542280]|[https://pubmed.ncbi.nlm.nih.gov/24411673 24411673]|[https://pubmed.ncbi.nlm.nih.gov/27760846 27760846]|[https://pubmed.ncbi.nlm.nih.gov/30115016 30115016]|[https://pubmed.ncbi.nlm.nih.gov/1410473 1410473]|[https://pubmed.ncbi.nlm.nih.gov/29802864 29802864]|[https://pubmed.ncbi.nlm.nih.gov/29669308 29669308]|[https://pubmed.ncbi.nlm.nih.gov/29251002 29251002]|[https://pubmed.ncbi.nlm.nih.gov/32541028 32541028]|[https://pubmed.ncbi.nlm.nih.gov/31019509 31019509]|[https://pubmed.ncbi.nlm.nih.gov/1582597 1582597]|[https://pubmed.ncbi.nlm.nih.gov/2981150 2981150]|[https://pubmed.ncbi.nlm.nih.gov/10842187 10842187]|[https://pubmed.ncbi.nlm.nih.gov/29638123 29638123]|[https://pubmed.ncbi.nlm.nih.gov/22367369 22367369]|[https://pubmed.ncbi.nlm.nih.gov/10778170 10778170]|[https://pubmed.ncbi.nlm.nih.gov/1510031 1510031]|[https://pubmed.ncbi.nlm.nih.gov/19372570 19372570]|[https://pubmed.ncbi.nlm.nih.gov/20641477 20641477]|[https://pubmed.ncbi.nlm.nih.gov/16149605 16149605]|[https://pubmed.ncbi.nlm.nih.gov/15770530 15770530]|[https://pubmed.ncbi.nlm.nih.gov/27856425 27856425]|[https://pubmed.ncbi.nlm.nih.gov/23814067 23814067]|[https://pubmed.ncbi.nlm.nih.gov/28068458 28068458]|[https://pubmed.ncbi.nlm.nih.gov/32134186 32134186]|[https://pubmed.ncbi.nlm.nih.gov/8174100 8174100]|[https://pubmed.ncbi.nlm.nih.gov/10571017 10571017]|[https://pubmed.ncbi.nlm.nih.gov/27453399 27453399]|[https://pubmed.ncbi.nlm.nih.gov/1727666 1727666]|[https://pubmed.ncbi.nlm.nih.gov/23740330 23740330] <br> | ||
'''definition''' : Tn anitigen or alpha-galnac or N-Acetylgalactosamine is an N-acetyl-D-galactosamine having alpha-configuration at the anomeric centre. It has a role as an epitope. It derives from an alpha-D-galactosamine.[CHEBI:40356, | '''definition''' : Tn anitigen or alpha-galnac or N-Acetylgalactosamine is an N-acetyl-D-galactosamine having alpha-configuration at the anomeric centre. It has a role as an epitope. It derives from an alpha-D-galactosamine.[CHEBI:40356,HMDB0000212] <br> | ||
'''term_xref''' : GTC:G57321FI|GlycoEpitope:EP0021|CID:84265|CHEBI:40356| | '''term_xref''' : GTC:G57321FI|GlycoEpitope:EP0021|CID:84265|CHEBI:40356|HMDB0000212|GlycoMotif:GGM.000008 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : lymphatic metastasis[GlycoEpitope:EP0021]|tube formation in Drosophila development[GlycoEpitope:EP0021]|modulation of malignant phenotype (gastric carcinoma cell)[GlycoEpitope:EP0021]|correlation with tumor stage, lymphatic invasion and lymph node matastasis[GlycoEpitope:EP0021] <br> | '''function''' : lymphatic metastasis[GlycoEpitope:EP0021]|tube formation in Drosophila development[GlycoEpitope:EP0021]|modulation of malignant phenotype (gastric carcinoma cell)[GlycoEpitope:EP0021]|correlation with tumor stage, lymphatic invasion and lymph node matastasis[GlycoEpitope:EP0021] <br> | ||
| Line 82: | Line 82: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.[PMID:24992960] <br> | '''term_in_sentence''' : Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.[PMID:24992960] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24992960 24992960]|[https://pubmed.ncbi.nlm.nih.gov/27025342 27025342]|[https://pubmed.ncbi.nlm.nih.gov/29642865 29642865]|[https://pubmed.ncbi.nlm.nih.gov/29456020 29456020]|[https://pubmed.ncbi.nlm.nih.gov/26914862 26914862]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/24992960 24992960]|[https://pubmed.ncbi.nlm.nih.gov/27025342 27025342]|[https://pubmed.ncbi.nlm.nih.gov/29642865 29642865]|[https://pubmed.ncbi.nlm.nih.gov/29456020 29456020]|[https://pubmed.ncbi.nlm.nih.gov/26914862 26914862]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/26299345 26299345]|[https://pubmed.ncbi.nlm.nih.gov/28981809 28981809]|[https://pubmed.ncbi.nlm.nih.gov/18395704 18395704]|[https://pubmed.ncbi.nlm.nih.gov/2211710 2211710]|[https://pubmed.ncbi.nlm.nih.gov/23461434 23461434]|[https://pubmed.ncbi.nlm.nih.gov/18327885 18327885]|[https://pubmed.ncbi.nlm.nih.gov/15264862 15264862]|[https://pubmed.ncbi.nlm.nih.gov/22954207 22954207]|[https://pubmed.ncbi.nlm.nih.gov/9061362 9061362]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/26537865 26537865]|[https://pubmed.ncbi.nlm.nih.gov/3979568 3979568]|[https://pubmed.ncbi.nlm.nih.gov/28129130 28129130]|[https://pubmed.ncbi.nlm.nih.gov/7679920 7679920]|[https://pubmed.ncbi.nlm.nih.gov/8068017 8068017]|[https://pubmed.ncbi.nlm.nih.gov/7783116 7783116]|[https://pubmed.ncbi.nlm.nih.gov/3857231 3857231]|[https://pubmed.ncbi.nlm.nih.gov/20540518 20540518]|[https://pubmed.ncbi.nlm.nih.gov/1706936 1706936]|[https://pubmed.ncbi.nlm.nih.gov/2430615 2430615]|[https://pubmed.ncbi.nlm.nih.gov/8078981 8078981]|[https://pubmed.ncbi.nlm.nih.gov/2211711 2211711]|[https://pubmed.ncbi.nlm.nih.gov/6767476 6767476]|[https://pubmed.ncbi.nlm.nih.gov/3814128 3814128]|[https://pubmed.ncbi.nlm.nih.gov/2597120 2597120]|[https://pubmed.ncbi.nlm.nih.gov/7451505 7451505]|[https://pubmed.ncbi.nlm.nih.gov/8204583 8204583]|[https://pubmed.ncbi.nlm.nih.gov/20619452 20619452]|[https://pubmed.ncbi.nlm.nih.gov/10460831 10460831]|[https://pubmed.ncbi.nlm.nih.gov/1924399 1924399]|[https://pubmed.ncbi.nlm.nih.gov/6643471 6643471]|[https://pubmed.ncbi.nlm.nih.gov/31809011 31809011]|[https://pubmed.ncbi.nlm.nih.gov/30042045 30042045]|[https://pubmed.ncbi.nlm.nih.gov/2477056 2477056]|[https://pubmed.ncbi.nlm.nih.gov/7882496 7882496]|[https://pubmed.ncbi.nlm.nih.gov/2430614 2430614]|[https://pubmed.ncbi.nlm.nih.gov/2551687 2551687]|[https://pubmed.ncbi.nlm.nih.gov/2426141 2426141]|[https://pubmed.ncbi.nlm.nih.gov/2065052 2065052]|[https://pubmed.ncbi.nlm.nih.gov/28988716 28988716]|[https://pubmed.ncbi.nlm.nih.gov/31144994 31144994]| [https://pubmed.ncbi.nlm.nih.gov/26966183 26966183]|[https://pubmed.ncbi.nlm.nih.gov/29809215 29809215] <br> | ||
'''definition''' : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br> | '''definition''' : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
| Line 97: | Line 97: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : Fucosylated biantennary complex-type and small amounts (less than 5%) of triantennary complex-type structures were identified on the glycosylated asparagine residues using sequential exoglycosidase and endoglycosidase digestions combined with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).[PMID:9118998] <br> | '''term_in_sentence''' : Fucosylated biantennary complex-type and small amounts (less than 5%) of triantennary complex-type structures were identified on the glycosylated asparagine residues using sequential exoglycosidase and endoglycosidase digestions combined with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).[PMID:9118998] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9118998 9118998]|[https://pubmed.ncbi.nlm.nih.gov/9061362 9061362]|[https://pubmed.ncbi.nlm.nih.gov/18395704 18395704]|[https://pubmed.ncbi.nlm.nih.gov/3814128 3814128]|[https://pubmed.ncbi.nlm.nih.gov/7451505 7451505]|[https://pubmed.ncbi.nlm.nih.gov/10460831 10460831]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/9118998 9118998]|[https://pubmed.ncbi.nlm.nih.gov/9061362 9061362]|[https://pubmed.ncbi.nlm.nih.gov/18395704 18395704]|[https://pubmed.ncbi.nlm.nih.gov/3814128 3814128]|[https://pubmed.ncbi.nlm.nih.gov/7451505 7451505]|[https://pubmed.ncbi.nlm.nih.gov/10460831 10460831]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183]|[https://pubmed.ncbi.nlm.nih.gov/16581187 16581187]|[https://pubmed.ncbi.nlm.nih.gov/16973123 16973123]|[https://pubmed.ncbi.nlm.nih.gov/8204583 8204583]|[https://pubmed.ncbi.nlm.nih.gov/29809215 29809215]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/11114588 11114588] [https://pubmed.ncbi.nlm.nih.gov/11114588 11114588]]|[https://pubmed.ncbi.nlm.nih.gov/31322324 31322324]|[https://pubmed.ncbi.nlm.nih.gov/15044389 15044389]|[https://pubmed.ncbi.nlm.nih.gov/16372382 16372382]|[https://pubmed.ncbi.nlm.nih.gov/8251489 8251489]|[https://pubmed.ncbi.nlm.nih.gov/8299583 8299583]|[https://pubmed.ncbi.nlm.nih.gov/1555586 1555586]|[https://pubmed.ncbi.nlm.nih.gov/7509658 7509658]|[https://pubmed.ncbi.nlm.nih.gov/1569060 1569060]|[https://pubmed.ncbi.nlm.nih.gov/16261636 16261636] <br> | ||
'''definition''' : A complex N-glycan that has three branches attached to the non-reducing terminal Man residues of the trimannosyl core.[CHEBI:156252] Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. <br> | '''definition''' : A complex N-glycan that has three branches attached to the non-reducing terminal Man residues of the trimannosyl core.[CHEBI:156252] Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. <br> | ||
'''term_xref''' : CHEBI:156252 <br> | '''term_xref''' : CHEBI:156252 <br> | ||
| Line 160: | Line 160: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1735443 1735443] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1735443 1735443] <br> | ||
'''definition''' : N-[(2R,3R,4R,5S,6R)-4-[(2R,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide is an amino sugar.[CHEBI:153783] <br> | '''definition''' : N-[(2R,3R,4R,5S,6R)-4-[(2R,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide is an amino sugar.[CHEBI:153783] <br> | ||
'''term_xref''' : GlycoEpitope:EP0092|GTC:G74578MX|CID: | '''term_xref''' : GlycoEpitope:EP0092|GTC:G74578MX|CID:91845957|CHEBI:153783 <br> | ||
'''synonyms''' : trifucosyl-Leb antigen <br> | '''synonyms''' : trifucosyl-Leb antigen <br> | ||
'''function''' : cancer-associated antigen[GlycoEpitope: EP0092] <br> | '''function''' : cancer-associated antigen[GlycoEpitope: EP0092] <br> | ||
| Line 176: | Line 176: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3733752 3733752]|[https://pubmed.ncbi.nlm.nih.gov/2426269 2426269]<br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3733752 3733752]|[https://pubmed.ncbi.nlm.nih.gov/2426269 2426269]<br> | ||
'''definition''' : A branched heptasaccharide derivative consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc (joined by a (1→3)-linkage) with an α-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.[CHEBI:61332] <br> | '''definition''' : A branched heptasaccharide derivative consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc (joined by a (1→3)-linkage) with an α-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.[CHEBI:61332] <br> | ||
'''term_xref''' : GlycoEpitope: EP0094|GTC:G74917JX|CID: | '''term_xref''' : GlycoEpitope: EP0094|GTC:G74917JX|CID:50909806|CHEBI:61332 <br> | ||
'''synonyms''' : trifucosyl Ley <br> | '''synonyms''' : trifucosyl Ley <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 204: | Line 204: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : Many (82.7%) were found to be tetraantennary N-acetyllactosamine-type (22.8% with one, 3.6% with two and 0.4% with three N-acetyllactosamine repeats) being tetrasialylated (41%), trisialylated (29.6%) and disialylated (12.2%) |HPAE-PAD and FACE analysis suggests that they are triantennary and trisialylated with core fucosylation.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8477709 8477709]] <br> | '''term_in_sentence''' : Many (82.7%) were found to be tetraantennary N-acetyllactosamine-type (22.8% with one, 3.6% with two and 0.4% with three N-acetyllactosamine repeats) being tetrasialylated (41%), trisialylated (29.6%) and disialylated (12.2%) |HPAE-PAD and FACE analysis suggests that they are triantennary and trisialylated with core fucosylation.[PMID:[https://pubmed.ncbi.nlm.nih.gov/8477709 8477709]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6469957 6469957]|[https://pubmed.ncbi.nlm.nih.gov/18818422 18818422]|[https://pubmed.ncbi.nlm.nih.gov/18332077 18332077]|[https://pubmed.ncbi.nlm.nih.gov/21138277 21138277]|[https://pubmed.ncbi.nlm.nih.gov/9136890 9136890]|[https://pubmed.ncbi.nlm.nih.gov/10782293 10782293]|[https://pubmed.ncbi.nlm.nih.gov/19841910 19841910]|[https://pubmed.ncbi.nlm.nih.gov/20067809 20067809]|[https://pubmed.ncbi.nlm.nih.gov/14751029 14751029]|[https://pubmed.ncbi.nlm.nih.gov/8797382 8797382]|[https://pubmed.ncbi.nlm.nih.gov/16877748 16877748]|[https://pubmed.ncbi.nlm.nih.gov/19131698 19131698]|[https://pubmed.ncbi.nlm.nih.gov/20578731 20578731]|[https://pubmed.ncbi.nlm.nih.gov/24669823 24669823]|[https://pubmed.ncbi.nlm.nih.gov/22426998 22426998]|[https://pubmed.ncbi.nlm.nih.gov/27501865 27501865]|[https://pubmed.ncbi.nlm.nih.gov/2121479 2121479]|[https://pubmed.ncbi.nlm.nih.gov/24663386 24663386]|[https://pubmed.ncbi.nlm.nih.gov/32209427 32209427]|[https://pubmed.ncbi.nlm.nih.gov/32737218 32737218]|[https://pubmed.ncbi.nlm.nih.gov/33245334 33245334]|[https://pubmed.ncbi.nlm.nih.gov/26927318 26927318]|[https://pubmed.ncbi.nlm.nih.gov/30962676 30962676]|[https://pubmed.ncbi.nlm.nih.gov/28370937 28370937]|[https://pubmed.ncbi.nlm.nih.gov/30194503 30194503]|[https://pubmed.ncbi.nlm.nih.gov/26321095 26321095]|[https://pubmed.ncbi.nlm.nih.gov/30463578 30463578]|[https://pubmed.ncbi.nlm.nih.gov/31455764 31455764]|[https://pubmed.ncbi.nlm.nih.gov/31566965 31566965]|[https://pubmed.ncbi.nlm.nih.gov/31266306 31266306]|[https://pubmed.ncbi.nlm.nih.gov/29782424 29782424]|[https://pubmed.ncbi.nlm.nih.gov/31247951 31247951]|[https://pubmed.ncbi.nlm.nih.gov/30487799 30487799]|[https://pubmed.ncbi.nlm.nih.gov/2049094 2049094]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/6469957 6469957]|[https://pubmed.ncbi.nlm.nih.gov/18818422 18818422]|[https://pubmed.ncbi.nlm.nih.gov/18332077 18332077]|[https://pubmed.ncbi.nlm.nih.gov/21138277 21138277]|[https://pubmed.ncbi.nlm.nih.gov/9136890 9136890]|[https://pubmed.ncbi.nlm.nih.gov/10782293 10782293]|[https://pubmed.ncbi.nlm.nih.gov/19841910 19841910]|[https://pubmed.ncbi.nlm.nih.gov/20067809 20067809]|[https://pubmed.ncbi.nlm.nih.gov/14751029 14751029]|[https://pubmed.ncbi.nlm.nih.gov/8797382 8797382]|[https://pubmed.ncbi.nlm.nih.gov/16877748 16877748]|[https://pubmed.ncbi.nlm.nih.gov/19131698 19131698]|[https://pubmed.ncbi.nlm.nih.gov/20578731 20578731]|[https://pubmed.ncbi.nlm.nih.gov/24669823 24669823]|[https://pubmed.ncbi.nlm.nih.gov/22426998 22426998]|[https://pubmed.ncbi.nlm.nih.gov/27501865 27501865]|[https://pubmed.ncbi.nlm.nih.gov/2121479 2121479]|[https://pubmed.ncbi.nlm.nih.gov/24663386 24663386]|[https://pubmed.ncbi.nlm.nih.gov/32209427 32209427]|[https://pubmed.ncbi.nlm.nih.gov/32737218 32737218]|[https://pubmed.ncbi.nlm.nih.gov/33245334 33245334]|[https://pubmed.ncbi.nlm.nih.gov/26927318 26927318]|[https://pubmed.ncbi.nlm.nih.gov/30962676 30962676]|[https://pubmed.ncbi.nlm.nih.gov/28370937 28370937]|[https://pubmed.ncbi.nlm.nih.gov/30194503 30194503]|[https://pubmed.ncbi.nlm.nih.gov/26321095 26321095]|[https://pubmed.ncbi.nlm.nih.gov/30463578 30463578]|[https://pubmed.ncbi.nlm.nih.gov/31455764 31455764]|[https://pubmed.ncbi.nlm.nih.gov/31566965 31566965]|[https://pubmed.ncbi.nlm.nih.gov/31266306 31266306]|[https://pubmed.ncbi.nlm.nih.gov/29782424 29782424]|[https://pubmed.ncbi.nlm.nih.gov/31247951 31247951]|[https://pubmed.ncbi.nlm.nih.gov/30487799 30487799]|[https://pubmed.ncbi.nlm.nih.gov/2049094 2049094]| [https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]|[https://pubmed.ncbi.nlm.nih.gov/10913832 10913832] <br> | ||
'''definition''' : A glycan with three sialic acid components. <br> | '''definition''' : A glycan with three sialic acid components. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
| Line 234: | Line 234: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : Determination of glycan primary structures and characterization of a new type of trisialylated diantennary glycan.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]] <br> | '''term_in_sentence''' : Determination of glycan primary structures and characterization of a new type of trisialylated diantennary glycan.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1997323 1997323]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1997323 1997323] <br> | ||
'''definition''' : A diantennary/biantennary glycans with three sialic acid components. <br> | '''definition''' : A diantennary/biantennary glycans with three sialic acid components. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
| Line 249: | Line 249: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : The N-glycans are of the complex type with the core-fucosylated disialylated biantennary and trisialylated triantennary structures predominating.[PMID:8942648] <br> | '''term_in_sentence''' : The N-glycans are of the complex type with the core-fucosylated disialylated biantennary and trisialylated triantennary structures predominating.[PMID:8942648] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30194503 30194503]|[https://pubmed.ncbi.nlm.nih.gov/27501865 27501865]|[https://pubmed.ncbi.nlm.nih.gov/10998266 10998266]|[https://pubmed.ncbi.nlm.nih.gov/20578731 20578731]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30194503 30194503]|[https://pubmed.ncbi.nlm.nih.gov/27501865 27501865]|[https://pubmed.ncbi.nlm.nih.gov/10998266 10998266]|[https://pubmed.ncbi.nlm.nih.gov/20578731 20578731]|[https://pubmed.ncbi.nlm.nih.gov/17591618 17591618]|[https://pubmed.ncbi.nlm.nih.gov/14751029 14751029]|[https://pubmed.ncbi.nlm.nih.gov/18818422 18818422]|[https://pubmed.ncbi.nlm.nih.gov/8942648 8942648]|[https://pubmed.ncbi.nlm.nih.gov/8900952 8900952] <br> | ||
'''definition''' : A triantennry glycan with three sialic acid components. <br> | '''definition''' : A triantennry glycan with three sialic acid components. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
| Line 266: | Line 266: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27834790 27834790]|[https://pubmed.ncbi.nlm.nih.gov/31523406 31523406]|[https://pubmed.ncbi.nlm.nih.gov/29978304 29978304]|[https://pubmed.ncbi.nlm.nih.gov/29575185 29575185]|[https://pubmed.ncbi.nlm.nih.gov/27326514 27326514]|[https://pubmed.ncbi.nlm.nih.gov/29029114 29029114]|[https://pubmed.ncbi.nlm.nih.gov/32450200 32450200]|[https://pubmed.ncbi.nlm.nih.gov/29432937 29432937]|[https://pubmed.ncbi.nlm.nih.gov/31906402 31906402]|[https://pubmed.ncbi.nlm.nih.gov/28739428 28739428]|[https://pubmed.ncbi.nlm.nih.gov/29298123 29298123]|[https://pubmed.ncbi.nlm.nih.gov/30976429 30976429]|[https://pubmed.ncbi.nlm.nih.gov/29091730 29091730]|[https://pubmed.ncbi.nlm.nih.gov/27770796 27770796]|[https://pubmed.ncbi.nlm.nih.gov/31330771 31330771]|[https://pubmed.ncbi.nlm.nih.gov/31138570 31138570]|[https://pubmed.ncbi.nlm.nih.gov/27154587 27154587]|[https://pubmed.ncbi.nlm.nih.gov/31542553 31542553]|[https://pubmed.ncbi.nlm.nih.gov/30519059 30519059]|[https://pubmed.ncbi.nlm.nih.gov/30590504 30590504]|[https://pubmed.ncbi.nlm.nih.gov/25880997 25880997]|[https://pubmed.ncbi.nlm.nih.gov/27490501 27490501]|[https://pubmed.ncbi.nlm.nih.gov/29981456 29981456]|[https://pubmed.ncbi.nlm.nih.gov/28559273 28559273]|[https://pubmed.ncbi.nlm.nih.gov/28193652 28193652]|[https://pubmed.ncbi.nlm.nih.gov/26638216 26638216]|[https://pubmed.ncbi.nlm.nih.gov/25897818 25897818]|[https://pubmed.ncbi.nlm.nih.gov/26238337 26238337]|[https://pubmed.ncbi.nlm.nih.gov/19553129 19553129]|[https://pubmed.ncbi.nlm.nih.gov/29644540 29644540]|[https://pubmed.ncbi.nlm.nih.gov/26242685 26242685]|[https://pubmed.ncbi.nlm.nih.gov/28487556 28487556]|[https://pubmed.ncbi.nlm.nih.gov/32622213 32622213]|[https://pubmed.ncbi.nlm.nih.gov/30248413 30248413]|[https://pubmed.ncbi.nlm.nih.gov/24762211 24762211]|[https://pubmed.ncbi.nlm.nih.gov/11451678 11451678]|[https://pubmed.ncbi.nlm.nih.gov/33169865 33169865]|[https://pubmed.ncbi.nlm.nih.gov/11897589 11897589]|[https://pubmed.ncbi.nlm.nih.gov/31479607 31479607] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27834790 27834790]|[https://pubmed.ncbi.nlm.nih.gov/31523406 31523406]|[https://pubmed.ncbi.nlm.nih.gov/29978304 29978304]|[https://pubmed.ncbi.nlm.nih.gov/29575185 29575185]|[https://pubmed.ncbi.nlm.nih.gov/27326514 27326514]|[https://pubmed.ncbi.nlm.nih.gov/29029114 29029114]|[https://pubmed.ncbi.nlm.nih.gov/32450200 32450200]|[https://pubmed.ncbi.nlm.nih.gov/29432937 29432937]|[https://pubmed.ncbi.nlm.nih.gov/31906402 31906402]|[https://pubmed.ncbi.nlm.nih.gov/28739428 28739428]|[https://pubmed.ncbi.nlm.nih.gov/29298123 29298123]|[https://pubmed.ncbi.nlm.nih.gov/30976429 30976429]|[https://pubmed.ncbi.nlm.nih.gov/29091730 29091730]|[https://pubmed.ncbi.nlm.nih.gov/27770796 27770796]|[https://pubmed.ncbi.nlm.nih.gov/31330771 31330771]|[https://pubmed.ncbi.nlm.nih.gov/31138570 31138570]|[https://pubmed.ncbi.nlm.nih.gov/27154587 27154587]|[https://pubmed.ncbi.nlm.nih.gov/31542553 31542553]|[https://pubmed.ncbi.nlm.nih.gov/30519059 30519059]|[https://pubmed.ncbi.nlm.nih.gov/30590504 30590504]|[https://pubmed.ncbi.nlm.nih.gov/25880997 25880997]|[https://pubmed.ncbi.nlm.nih.gov/27490501 27490501]|[https://pubmed.ncbi.nlm.nih.gov/29981456 29981456]|[https://pubmed.ncbi.nlm.nih.gov/28559273 28559273]|[https://pubmed.ncbi.nlm.nih.gov/28193652 28193652]|[https://pubmed.ncbi.nlm.nih.gov/26638216 26638216]|[https://pubmed.ncbi.nlm.nih.gov/25897818 25897818]|[https://pubmed.ncbi.nlm.nih.gov/26238337 26238337]|[https://pubmed.ncbi.nlm.nih.gov/19553129 19553129]|[https://pubmed.ncbi.nlm.nih.gov/29644540 29644540]|[https://pubmed.ncbi.nlm.nih.gov/26242685 26242685]|[https://pubmed.ncbi.nlm.nih.gov/28487556 28487556]|[https://pubmed.ncbi.nlm.nih.gov/32622213 32622213]|[https://pubmed.ncbi.nlm.nih.gov/30248413 30248413]|[https://pubmed.ncbi.nlm.nih.gov/24762211 24762211]|[https://pubmed.ncbi.nlm.nih.gov/11451678 11451678]|[https://pubmed.ncbi.nlm.nih.gov/33169865 33169865]|[https://pubmed.ncbi.nlm.nih.gov/11897589 11897589]|[https://pubmed.ncbi.nlm.nih.gov/31479607 31479607] <br> | ||
'''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the N-acetyl-D-glucosamine residue at the reducing end is β.[CHEBI:85946] <br> | '''definition''' : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the N-acetyl-D-glucosamine residue at the reducing end is β.[CHEBI:85946] <br> | ||
'''term_xref''' : GTC:G22418PV |GlycoEpitope:EP0019|CID: | '''term_xref''' : GTC:G22418PV |GlycoEpitope:EP0019|CID:91825708|CHEBI:85946|GlycoMotif:GGM.000033 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : CDw65 have been shown to interact with the ELAM-1 molecule on activated endothelium.[GlycoEpitope:EP0019] <br> | '''function''' : CDw65 have been shown to interact with the ELAM-1 molecule on activated endothelium.[GlycoEpitope:EP0019] <br> | ||
| Line 309: | Line 309: | ||
'''glycan_dictionary_accession''' : GSD000003 <br> | '''glycan_dictionary_accession''' : GSD000003 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G67383AR G67383AR] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G67383AR G67383AR] <br> | ||
'''term_in_sentence''' : They were fucosyl-Gv., fucoSyl-GDlb, and two uni que fucogangliosides having GMl or GOlb bas ic structure containing a substituent with the blood group B determinant. [PMID: | '''term_in_sentence''' : They were fucosyl-Gv., fucoSyl-GDlb, and two uni que fucogangliosides having GMl or GOlb bas ic structure containing a substituent with the blood group B determinant. [PMID:[https://pubmed.ncbi.nlm.nih.gov/3654655 3654655]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3654655 3654655] <br> | ||
'''definition''' : (2S,4S,5R,6R)-5-Acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxyoxane-2-carboxylic acid.[CHEBI:156680] <br> | '''definition''' : (2S,4S,5R,6R)-5-Acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxyoxane-2-carboxylic acid.[CHEBI:156680] <br> | ||
'''term_xref''' : CHEBI:156680|GlycoMotif:GGM.000103|GTC:G67383AR<br> | '''term_xref''' : CHEBI:156680|GlycoMotif:GGM.000103|GTC:G67383AR<br> | ||
| Line 324: | Line 324: | ||
'''glycan_dictionary_accession''' : GSD000004 <br> | '''glycan_dictionary_accession''' : GSD000004 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G56526JU G56526JU] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G56526JU G56526JU] <br> | ||
'''term_in_sentence''' : These glycolipid products were identified as asialo-Gs.., GM h and fucosyl-Gq, by comparison with authentic glycolipid samples.[PMID: | '''term_in_sentence''' : These glycolipid products were identified as asialo-Gs.., GM h and fucosyl-Gq, by comparison with authentic glycolipid samples.[PMID:[https://pubmed.ncbi.nlm.nih.gov/3654655 3654655]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3654655 3654655] <br> | ||
'''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:151476] <br> | '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:151476] <br> | ||
'''term_xref''' : KEGG:G12241|CHEBI:151476|CID: | '''term_xref''' : KEGG:G12241|CHEBI:151476|CID:91849786|GlycoMotif:GGM.000101|GTC:G56526JU <br> | ||
'''synonyms''' : Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-3)]Gal(b1-4)Glc|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose <br> | '''synonyms''' : Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-3)]Gal(b1-4)Glc|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 354: | Line 354: | ||
'''glycan_dictionary_accession''' : GSD000006 <br> | '''glycan_dictionary_accession''' : GSD000006 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78706CK G78706CK] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G78706CK G78706CK] <br> | ||
'''term_in_sentence''' : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID: | '''term_in_sentence''' : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]|[https://pubmed.ncbi.nlm.nih.gov/17499486 17499486]|[https://pubmed.ncbi.nlm.nih.gov/17691854 17691854]|[https://pubmed.ncbi.nlm.nih.gov/12944557 12944557]|[https://pubmed.ncbi.nlm.nih.gov/19394320 19394320]|[https://pubmed.ncbi.nlm.nih.gov/7534477 7534477]|[https://pubmed.ncbi.nlm.nih.gov/11604107 11604107]|[https://pubmed.ncbi.nlm.nih.gov/28025252 28025252]|[https://pubmed.ncbi.nlm.nih.gov/9061363 9061363]|[https://pubmed.ncbi.nlm.nih.gov/9878545 9878545]|[https://pubmed.ncbi.nlm.nih.gov/11918697 11918697]|[https://pubmed.ncbi.nlm.nih.gov/24239607 24239607]|[https://pubmed.ncbi.nlm.nih.gov/28628803 28628803]|[https://pubmed.ncbi.nlm.nih.gov/25339106 25339106]|[https://pubmed.ncbi.nlm.nih.gov/21400496 21400496]|[https://pubmed.ncbi.nlm.nih.gov/17998215 17998215]|[https://pubmed.ncbi.nlm.nih.gov/12626387 12626387]|[https://pubmed.ncbi.nlm.nih.gov/11425799 11425799]|[https://pubmed.ncbi.nlm.nih.gov/12219077 12219077]|[https://pubmed.ncbi.nlm.nih.gov/10955596 10955596]|[https://pubmed.ncbi.nlm.nih.gov/9453593 9453593] <br> | ||
'''definition''' : A branched amino trisaccharide consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an α-linkage and a 3-sulfated galactosyl residue attached at the 3-position via a β-linkage.[CHEBI:65149] <br> | '''definition''' : A branched amino trisaccharide consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an α-linkage and a 3-sulfated galactosyl residue attached at the 3-position via a β-linkage.[CHEBI:65149] <br> | ||
'''term_xref''' : GTC:G78706CK|GlycoEpitope:EP0009|CID: | '''term_xref''' : GTC:G78706CK|GlycoEpitope:EP0009|CID:5289352|GlycoMotif:GGM.000030 <br> | ||
'''synonyms''' : 3'-Sulfo-Lea|SuLe(a)|3'-sulpho-Le(a)|3-O-sulfo-Le(A)|3'-Sulfo Le^a|3'-Sulfo Lea|3'-Sulfo Lewis a <br> | '''synonyms''' : 3'-Sulfo-Lea|SuLe(a)|3'-sulpho-Le(a)|3-O-sulfo-Le(A)|3'-Sulfo Le^a|3'-Sulfo Lea|3'-Sulfo Lewis a <br> | ||
'''function''' : SO3-3-Gal and the SO3-3-Lea blood group antigen bound to H.pylori.[GlycoEpitope:EP0009] <br> | '''function''' : SO3-3-Gal and the SO3-3-Lea blood group antigen bound to H.pylori.[GlycoEpitope:EP0009] <br> | ||
| Line 369: | Line 369: | ||
'''glycan_dictionary_accession''' : GSD000007 <br> | '''glycan_dictionary_accession''' : GSD000007 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G12295TB G12295TB] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G12295TB G12295TB] <br> | ||
'''term_in_sentence''' : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID: | '''term_in_sentence''' : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/11504739 11504739]|[https://pubmed.ncbi.nlm.nih.gov/20695481 20695481]|[https://pubmed.ncbi.nlm.nih.gov/8688428 8688428]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036] [https://pubmed.ncbi.nlm.nih.gov/10536036 10536036]]|[https://pubmed.ncbi.nlm.nih.gov/12770775 12770775]|[https://pubmed.ncbi.nlm.nih.gov/11352731 11352731]|[https://pubmed.ncbi.nlm.nih.gov/9784103 9784103]|[https://pubmed.ncbi.nlm.nih.gov/9022803 9022803] <br> | ||
'''definition''' : An amino trisaccharide that consists of ''N''-acetyl-β-<small>D</small>-glucosamine having an α-<small>L</small>-fucosyl residue attached at position 3 and a 3-sulfated β-<small>D</small>-galactosyl residue attached at position 4; β-<small>D</small>-Gal''p''3S-(1→4)-[α-<small>L</small>-Fuc''p''-(1→3)]-<small>D</small>-Glc''p''NAc in which the configuration at the anomeric centre of the reducing-end residue is β. [CHEBI:65171] <br> | '''definition''' : An amino trisaccharide that consists of ''N''-acetyl-β-<small>D</small>-glucosamine having an α-<small>L</small>-fucosyl residue attached at position 3 and a 3-sulfated β-<small>D</small>-galactosyl residue attached at position 4; β-<small>D</small>-Gal''p''3S-(1→4)-[α-<small>L</small>-Fuc''p''-(1→3)]-<small>D</small>-Glc''p''NAc in which the configuration at the anomeric centre of the reducing-end residue is β. [CHEBI:65171] <br> | ||
'''term_xref''' : GTC:G12295TB|GlycoEpitope:EP0013|CID: | '''term_xref''' : GTC:G12295TB|GlycoEpitope:EP0013|CID:5289353|CHEBI:65171|GlycoMotif:GGM.000029 <br> | ||
'''synonyms''' : 3'-sulfo-Le(x)|3'-Sulfo Lewis x|3'-sulfo Le^x|3'-sulfo Lex <br> | '''synonyms''' : 3'-sulfo-Le(x)|3'-Sulfo Lewis x|3'-sulfo Le^x|3'-sulfo Lex <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 384: | Line 384: | ||
'''glycan_dictionary_accession''' : GSD000008 <br> | '''glycan_dictionary_accession''' : GSD000008 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00659GQ G00659GQ] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00659GQ G00659GQ] <br> | ||
'''term_in_sentence''' : Comparison of the reactivity pattern of HEV with the reactivity of the pure 6-sulfo, 6'-sulfo, or 6,6'-bissulfo sialyl Lewis X determinant with hitherto known anti-sialyl Lewis X antibodies strongly suggested 6-sulfo sialyl Lewis X to be the best candidate for the major sulfated sialyl Lewis X determinant on HEV, followed by 6,6'-bissulfo sialyl Lewis X, whereas 6'-sulfo sialyl Lewis X was unlikely. [PMID: | '''term_in_sentence''' : Comparison of the reactivity pattern of HEV with the reactivity of the pure 6-sulfo, 6'-sulfo, or 6,6'-bissulfo sialyl Lewis X determinant with hitherto known anti-sialyl Lewis X antibodies strongly suggested 6-sulfo sialyl Lewis X to be the best candidate for the major sulfated sialyl Lewis X determinant on HEV, followed by 6,6'-bissulfo sialyl Lewis X, whereas 6'-sulfo sialyl Lewis X was unlikely. [PMID:[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19756298 19756298]|[https://pubmed.ncbi.nlm.nih.gov/14593101 14593101]|[https://pubmed.ncbi.nlm.nih.gov/15175329 15175329]|[https://pubmed.ncbi.nlm.nih.gov/14568956 14568956]|[https://pubmed.ncbi.nlm.nih.gov/12163379 12163379]|[https://pubmed.ncbi.nlm.nih.gov/11919403 11919403]|[https://pubmed.ncbi.nlm.nih.gov/11520459 11520459]|[https://pubmed.ncbi.nlm.nih.gov/10728707 10728707]|[https://pubmed.ncbi.nlm.nih.gov/10200296 10200296]|[https://pubmed.ncbi.nlm.nih.gov/10528213 10528213]|[https://pubmed.ncbi.nlm.nih.gov/9712885 9712885]| [https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/9257857 9257857]|[https://pubmed.ncbi.nlm.nih.gov/9164959 9164959]|[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359]|[https://pubmed.ncbi.nlm.nih.gov/8958810 8958810]|[https://pubmed.ncbi.nlm.nih.gov/7560094 7560094]|[https://pubmed.ncbi.nlm.nih.gov/7485559 7485559]|[https://pubmed.ncbi.nlm.nih.gov/7538131 7538131]|[https://pubmed.ncbi.nlm.nih.gov/8161542 8161542]|[https://pubmed.ncbi.nlm.nih.gov/7684905 7684905] <br> | ||
'''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(sulfooxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(sulfooxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:146095] <br> | '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(sulfooxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(sulfooxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:146095] <br> | ||
'''term_xref''' : GlycoEpitope:EP0016|CHEBI:146095|GlycoMotif:GGM.000028|GTC:G00659GQ <br> | '''term_xref''' : GlycoEpitope:EP0016|CHEBI:146095|GlycoMotif:GGM.000028|GTC:G00659GQ <br> | ||
| Line 402: | Line 402: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1618643 1618643]|[https://pubmed.ncbi.nlm.nih.gov/6194157 6194157] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1618643 1618643]|[https://pubmed.ncbi.nlm.nih.gov/6194157 6194157] <br> | ||
'''definition''' : An amino disaccharide composed of N-acetylneuraminic acid and 2-(acetylamino)-2-deoxy-D-galactopyranose residues joined by an (α-2→6) glycosidic bond.[CHEBI:146820] <br> | '''definition''' : An amino disaccharide composed of N-acetylneuraminic acid and 2-(acetylamino)-2-deoxy-D-galactopyranose residues joined by an (α-2→6) glycosidic bond.[CHEBI:146820] <br> | ||
'''term_xref''' : GlycoEpitope:EP0352|KEGG:G00455|KEGG:G10625|CHEBI:146820|CID: | '''term_xref''' : GlycoEpitope:EP0352|KEGG:G00455|KEGG:G10625|CHEBI:146820|CID:11409652|GlycoMotif:GGM.000035|GTC:G08371CD <br> | ||
'''synonyms''' : Sialyl Tn antigen|6-Sialyl-GalNAc|6-Sialyl LN|6-Sialyl LN (type 1)|6-Sialyl LN (type 2) <br> | '''synonyms''' : Sialyl Tn antigen|6-Sialyl-GalNAc|6-Sialyl LN|6-Sialyl LN (type 1)|6-Sialyl LN (type 2) <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 417: | Line 417: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31572354 31572354]|[https://pubmed.ncbi.nlm.nih.gov/31191513 31191513]|[https://pubmed.ncbi.nlm.nih.gov/29977237 29977237]|[https://pubmed.ncbi.nlm.nih.gov/29900053 29900053]|[https://pubmed.ncbi.nlm.nih.gov/30984181 30984181]|[https://pubmed.ncbi.nlm.nih.gov/28732748 28732748]|[https://pubmed.ncbi.nlm.nih.gov/26510404 26510404]|[https://pubmed.ncbi.nlm.nih.gov/28769928 28769928]|[https://pubmed.ncbi.nlm.nih.gov/31154896 31154896]|[https://pubmed.ncbi.nlm.nih.gov/27541644 27541644]|[https://pubmed.ncbi.nlm.nih.gov/25262889 25262889]|[https://pubmed.ncbi.nlm.nih.gov/26155414 26155414]|[https://pubmed.ncbi.nlm.nih.gov/28499587 28499587]|[https://pubmed.ncbi.nlm.nih.gov/27086951 27086951]|[https://pubmed.ncbi.nlm.nih.gov/27315572 27315572]|[https://pubmed.ncbi.nlm.nih.gov/26162403 26162403]|[https://pubmed.ncbi.nlm.nih.gov/26391152 26391152]|[https://pubmed.ncbi.nlm.nih.gov/31730025 31730025]|[https://pubmed.ncbi.nlm.nih.gov/12354382 12354382]|[https://pubmed.ncbi.nlm.nih.gov/27318477 27318477]|[https://pubmed.ncbi.nlm.nih.gov/23879812 23879812]|[https://pubmed.ncbi.nlm.nih.gov/25340085 25340085]|[https://pubmed.ncbi.nlm.nih.gov/24682513 24682513]|[https://pubmed.ncbi.nlm.nih.gov/21377044 21377044]|[https://pubmed.ncbi.nlm.nih.gov/21098395 21098395]|[https://pubmed.ncbi.nlm.nih.gov/18942710 18942710]|[https://pubmed.ncbi.nlm.nih.gov/23559493 23559493]|[https://pubmed.ncbi.nlm.nih.gov/23890755 23890755]|[https://pubmed.ncbi.nlm.nih.gov/22643330 22643330]|[https://pubmed.ncbi.nlm.nih.gov/23460612 23460612]|[https://pubmed.ncbi.nlm.nih.gov/23402811 23402811]|[https://pubmed.ncbi.nlm.nih.gov/22890025 22890025]|[https://pubmed.ncbi.nlm.nih.gov/19589615 19589615]|[https://pubmed.ncbi.nlm.nih.gov/32939325 32939325]|[https://pubmed.ncbi.nlm.nih.gov/20210806 20210806]|[https://pubmed.ncbi.nlm.nih.gov/17616642 17616642]|[https://pubmed.ncbi.nlm.nih.gov/22907335 22907335]|[https://pubmed.ncbi.nlm.nih.gov/16782032 16782032]|[https://pubmed.ncbi.nlm.nih.gov/22188261 22188261]|[https://pubmed.ncbi.nlm.nih.gov/21283706 21283706]|[https://pubmed.ncbi.nlm.nih.gov/29875315 29875315]|[https://pubmed.ncbi.nlm.nih.gov/32413173 32413173]|[https://pubmed.ncbi.nlm.nih.gov/19546436 19546436]|[https://pubmed.ncbi.nlm.nih.gov/19384158 19384158]|[https://pubmed.ncbi.nlm.nih.gov/1429720 1429720]|[https://pubmed.ncbi.nlm.nih.gov/30519676 30519676] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31572354 31572354]|[https://pubmed.ncbi.nlm.nih.gov/31191513 31191513]|[https://pubmed.ncbi.nlm.nih.gov/29977237 29977237]|[https://pubmed.ncbi.nlm.nih.gov/29900053 29900053]|[https://pubmed.ncbi.nlm.nih.gov/30984181 30984181]|[https://pubmed.ncbi.nlm.nih.gov/28732748 28732748]|[https://pubmed.ncbi.nlm.nih.gov/26510404 26510404]|[https://pubmed.ncbi.nlm.nih.gov/28769928 28769928]|[https://pubmed.ncbi.nlm.nih.gov/31154896 31154896]|[https://pubmed.ncbi.nlm.nih.gov/27541644 27541644]|[https://pubmed.ncbi.nlm.nih.gov/25262889 25262889]|[https://pubmed.ncbi.nlm.nih.gov/26155414 26155414]|[https://pubmed.ncbi.nlm.nih.gov/28499587 28499587]|[https://pubmed.ncbi.nlm.nih.gov/27086951 27086951]|[https://pubmed.ncbi.nlm.nih.gov/27315572 27315572]|[https://pubmed.ncbi.nlm.nih.gov/26162403 26162403]|[https://pubmed.ncbi.nlm.nih.gov/26391152 26391152]|[https://pubmed.ncbi.nlm.nih.gov/31730025 31730025]|[https://pubmed.ncbi.nlm.nih.gov/12354382 12354382]|[https://pubmed.ncbi.nlm.nih.gov/27318477 27318477]|[https://pubmed.ncbi.nlm.nih.gov/23879812 23879812]|[https://pubmed.ncbi.nlm.nih.gov/25340085 25340085]|[https://pubmed.ncbi.nlm.nih.gov/24682513 24682513]|[https://pubmed.ncbi.nlm.nih.gov/21377044 21377044]|[https://pubmed.ncbi.nlm.nih.gov/21098395 21098395]|[https://pubmed.ncbi.nlm.nih.gov/18942710 18942710]|[https://pubmed.ncbi.nlm.nih.gov/23559493 23559493]|[https://pubmed.ncbi.nlm.nih.gov/23890755 23890755]|[https://pubmed.ncbi.nlm.nih.gov/22643330 22643330]|[https://pubmed.ncbi.nlm.nih.gov/23460612 23460612]|[https://pubmed.ncbi.nlm.nih.gov/23402811 23402811]|[https://pubmed.ncbi.nlm.nih.gov/22890025 22890025]|[https://pubmed.ncbi.nlm.nih.gov/19589615 19589615]|[https://pubmed.ncbi.nlm.nih.gov/32939325 32939325]|[https://pubmed.ncbi.nlm.nih.gov/20210806 20210806]|[https://pubmed.ncbi.nlm.nih.gov/17616642 17616642]|[https://pubmed.ncbi.nlm.nih.gov/22907335 22907335]|[https://pubmed.ncbi.nlm.nih.gov/16782032 16782032]|[https://pubmed.ncbi.nlm.nih.gov/22188261 22188261]|[https://pubmed.ncbi.nlm.nih.gov/21283706 21283706]|[https://pubmed.ncbi.nlm.nih.gov/29875315 29875315]|[https://pubmed.ncbi.nlm.nih.gov/32413173 32413173]|[https://pubmed.ncbi.nlm.nih.gov/19546436 19546436]|[https://pubmed.ncbi.nlm.nih.gov/19384158 19384158]|[https://pubmed.ncbi.nlm.nih.gov/1429720 1429720]|[https://pubmed.ncbi.nlm.nih.gov/30519676 30519676] <br> | ||
'''definition''' : An oligosaccharide sulfate that is N-acetyllactosamine in which the hydroxy group at position 6 of the N-acetylglucosamine ring has been converted into its hydrogen sulfate derivative.[CHEBI:148005] <br> | '''definition''' : An oligosaccharide sulfate that is N-acetyllactosamine in which the hydroxy group at position 6 of the N-acetylglucosamine ring has been converted into its hydrogen sulfate derivative.[CHEBI:148005] <br> | ||
'''term_xref''' : GlycoEpitope:EP0141|GTC:G13157WZ|CID: | '''term_xref''' : GlycoEpitope:EP0141|GTC:G13157WZ|CID:10322152|CHEBI:148005<br> | ||
'''synonyms''' : 6-Sulfo LacNAc <br> | '''synonyms''' : 6-Sulfo LacNAc <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 431: | Line 431: | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00672PE G00672PE] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G00672PE G00672PE] <br> | ||
'''term_in_sentence''' : Studies using sulfotransferase-deficient mice showed that 6-sulfo sialyl Lewis X (6-sulfo sLe(x)), a major ligand for L-selectin that is expressed on the high endothelial venules (HEVs), plays critical roles in lymphocyte homing to the peripheral lymph nodes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2288521 2288521]] <br> | '''term_in_sentence''' : Studies using sulfotransferase-deficient mice showed that 6-sulfo sialyl Lewis X (6-sulfo sLe(x)), a major ligand for L-selectin that is expressed on the high endothelial venules (HEVs), plays critical roles in lymphocyte homing to the peripheral lymph nodes.[PMID:[https://pubmed.ncbi.nlm.nih.gov/2288521 2288521]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2288521 2288521]|[https://pubmed.ncbi.nlm.nih.gov/26137907 26137907]|[https://pubmed.ncbi.nlm.nih.gov/9400621 9400621]|[https://pubmed.ncbi.nlm.nih.gov/32744401 32744401]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2288521 2288521]|[https://pubmed.ncbi.nlm.nih.gov/26137907 26137907]|[https://pubmed.ncbi.nlm.nih.gov/9400621 9400621]|[https://pubmed.ncbi.nlm.nih.gov/32744401 32744401]|[https://pubmed.ncbi.nlm.nih.gov/9556613 9556613]|[https://pubmed.ncbi.nlm.nih.gov/15972893 15972893]|[https://pubmed.ncbi.nlm.nih.gov/9015359 9015359]|[https://pubmed.ncbi.nlm.nih.gov/22691873 22691873]|[https://pubmed.ncbi.nlm.nih.gov/18652681 18652681]|[https://pubmed.ncbi.nlm.nih.gov/9722682 9722682]|[https://pubmed.ncbi.nlm.nih.gov/10435581 10435581]|[https://pubmed.ncbi.nlm.nih.gov/19458105 19458105]|[https://pubmed.ncbi.nlm.nih.gov/19359410 19359410]|[https://pubmed.ncbi.nlm.nih.gov/15228275 15228275]|[https://pubmed.ncbi.nlm.nih.gov/18250165 18250165]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036] [https://pubmed.ncbi.nlm.nih.gov/10536036 10536036]]|[https://pubmed.ncbi.nlm.nih.gov/17944600 17944600]|[https://pubmed.ncbi.nlm.nih.gov/10460836 10460836]|[https://pubmed.ncbi.nlm.nih.gov/27993973 27993973]|[https://pubmed.ncbi.nlm.nih.gov/19149511 19149511]|[https://pubmed.ncbi.nlm.nih.gov/19150806 19150806]|[https://pubmed.ncbi.nlm.nih.gov/17172261 17172261]|[https://pubmed.ncbi.nlm.nih.gov/17142960 17142960]|[https://pubmed.ncbi.nlm.nih.gov/27956273 27956273]|[https://pubmed.ncbi.nlm.nih.gov/7578028 7578028]|[https://pubmed.ncbi.nlm.nih.gov/22260995 22260995]|[https://pubmed.ncbi.nlm.nih.gov/24519996 24519996]|[https://pubmed.ncbi.nlm.nih.gov/21596021 21596021]|[https://pubmed.ncbi.nlm.nih.gov/21982762 21982762]|[https://pubmed.ncbi.nlm.nih.gov/21775439 21775439]|[https://pubmed.ncbi.nlm.nih.gov/17334369 17334369]|[https://pubmed.ncbi.nlm.nih.gov/9710564 9710564]|[https://pubmed.ncbi.nlm.nih.gov/14593101 14593101]|[https://pubmed.ncbi.nlm.nih.gov/16227985 16227985]|[https://pubmed.ncbi.nlm.nih.gov/11895802 11895802]|[https://pubmed.ncbi.nlm.nih.gov/22750968 22750968]|[https://pubmed.ncbi.nlm.nih.gov/15157883 15157883]|[https://pubmed.ncbi.nlm.nih.gov/19067429 19067429] <br> | ||
'''definition''' : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, 6-O-sulfo-β-D-glactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the GlcNAC residue of which is also linked (1→3) an α-L-fucose residue.[CHEBI:71558] <br> | '''definition''' : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, 6-O-sulfo-β-D-glactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the GlcNAC residue of which is also linked (1→3) an α-L-fucose residue.[CHEBI:71558] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000025|GTC:G00672PE|CID: | '''term_xref''' : GlycoMotif:GGM.000025|GTC:G00672PE|CID:70698387|GlycoEpitope:EP0014|CHEBI:71558|SugarBind_Ligand:128 <br> | ||
'''synonyms''' : 6'-sulfated sialyl Lewis x-|6'-sulfo-sLe(x)|Su-SaiLex|Su-Slex|6'-Sulfo-sialyl Lewis x <br> | '''synonyms''' : 6'-sulfated sialyl Lewis x-|6'-sulfo-sLe(x)|Su-SaiLex|Su-Slex|6'-Sulfo-sialyl Lewis x <br> | ||
'''function''' : lymphocyte homing[GlycoEpitope:EP0014] <br> | '''function''' : lymphocyte homing[GlycoEpitope:EP0014] <br> | ||
| Line 448: | Line 448: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16432837 16432837]|[https://pubmed.ncbi.nlm.nih.gov/21507905 21507905]|[https://pubmed.ncbi.nlm.nih.gov/17512674 17512674]|[https://pubmed.ncbi.nlm.nih.gov/21930212 21930212]|[https://pubmed.ncbi.nlm.nih.gov/18194438 18194438]|[https://pubmed.ncbi.nlm.nih.gov/20739294 20739294]|[https://pubmed.ncbi.nlm.nih.gov/3216430 3216430]|[https://pubmed.ncbi.nlm.nih.gov/14724245 14724245]|[https://pubmed.ncbi.nlm.nih.gov/31373393 31373393]|[https://pubmed.ncbi.nlm.nih.gov/7558412 7558412]|[https://pubmed.ncbi.nlm.nih.gov/11273644 11273644]|[https://pubmed.ncbi.nlm.nih.gov/17385751 17385751]|[https://pubmed.ncbi.nlm.nih.gov/30694652 30694652]|[https://pubmed.ncbi.nlm.nih.gov/22894715 22894715]|[https://pubmed.ncbi.nlm.nih.gov/12973826 12973826]|[https://pubmed.ncbi.nlm.nih.gov/7859075 7859075]|[https://pubmed.ncbi.nlm.nih.gov/9749956 9749956]|[https://pubmed.ncbi.nlm.nih.gov/9874495 9874495]|[https://pubmed.ncbi.nlm.nih.gov/12486096 12486096]|[https://pubmed.ncbi.nlm.nih.gov/1989525 1989525]|[https://pubmed.ncbi.nlm.nih.gov/25330147 25330147]|[https://pubmed.ncbi.nlm.nih.gov/23478187 23478187]|[https://pubmed.ncbi.nlm.nih.gov/21807667 21807667]|[https://pubmed.ncbi.nlm.nih.gov/8486686 8486686]|[https://pubmed.ncbi.nlm.nih.gov/11465673 11465673]|[https://pubmed.ncbi.nlm.nih.gov/9511990 9511990]|[https://pubmed.ncbi.nlm.nih.gov/29270199 29270199]|[https://pubmed.ncbi.nlm.nih.gov/9268945 9268945]|[https://pubmed.ncbi.nlm.nih.gov/25045067 25045067]|[https://pubmed.ncbi.nlm.nih.gov/21618115 21618115]|[https://pubmed.ncbi.nlm.nih.gov/16434401 16434401]|[https://pubmed.ncbi.nlm.nih.gov/12493756 12493756]|[https://pubmed.ncbi.nlm.nih.gov/2302705 2302705]|[https://pubmed.ncbi.nlm.nih.gov/2198284 2198284]|[https://pubmed.ncbi.nlm.nih.gov/2685488 2685488]|[https://pubmed.ncbi.nlm.nih.gov/9328574 9328574]|[https://pubmed.ncbi.nlm.nih.gov/4055789 4055789]|[https://pubmed.ncbi.nlm.nih.gov/10096568 10096568]|[https://pubmed.ncbi.nlm.nih.gov/1644805 1644805]|[https://pubmed.ncbi.nlm.nih.gov/2582447 2582447] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16432837 16432837]|[https://pubmed.ncbi.nlm.nih.gov/21507905 21507905]|[https://pubmed.ncbi.nlm.nih.gov/17512674 17512674]|[https://pubmed.ncbi.nlm.nih.gov/21930212 21930212]|[https://pubmed.ncbi.nlm.nih.gov/18194438 18194438]|[https://pubmed.ncbi.nlm.nih.gov/20739294 20739294]|[https://pubmed.ncbi.nlm.nih.gov/3216430 3216430]|[https://pubmed.ncbi.nlm.nih.gov/14724245 14724245]|[https://pubmed.ncbi.nlm.nih.gov/31373393 31373393]|[https://pubmed.ncbi.nlm.nih.gov/7558412 7558412]|[https://pubmed.ncbi.nlm.nih.gov/11273644 11273644]|[https://pubmed.ncbi.nlm.nih.gov/17385751 17385751]|[https://pubmed.ncbi.nlm.nih.gov/30694652 30694652]|[https://pubmed.ncbi.nlm.nih.gov/22894715 22894715]|[https://pubmed.ncbi.nlm.nih.gov/12973826 12973826]|[https://pubmed.ncbi.nlm.nih.gov/7859075 7859075]|[https://pubmed.ncbi.nlm.nih.gov/9749956 9749956]|[https://pubmed.ncbi.nlm.nih.gov/9874495 9874495]|[https://pubmed.ncbi.nlm.nih.gov/12486096 12486096]|[https://pubmed.ncbi.nlm.nih.gov/1989525 1989525]|[https://pubmed.ncbi.nlm.nih.gov/25330147 25330147]|[https://pubmed.ncbi.nlm.nih.gov/23478187 23478187]|[https://pubmed.ncbi.nlm.nih.gov/21807667 21807667]|[https://pubmed.ncbi.nlm.nih.gov/8486686 8486686]|[https://pubmed.ncbi.nlm.nih.gov/11465673 11465673]|[https://pubmed.ncbi.nlm.nih.gov/9511990 9511990]|[https://pubmed.ncbi.nlm.nih.gov/29270199 29270199]|[https://pubmed.ncbi.nlm.nih.gov/9268945 9268945]|[https://pubmed.ncbi.nlm.nih.gov/25045067 25045067]|[https://pubmed.ncbi.nlm.nih.gov/21618115 21618115]|[https://pubmed.ncbi.nlm.nih.gov/16434401 16434401]|[https://pubmed.ncbi.nlm.nih.gov/12493756 12493756]|[https://pubmed.ncbi.nlm.nih.gov/2302705 2302705]|[https://pubmed.ncbi.nlm.nih.gov/2198284 2198284]|[https://pubmed.ncbi.nlm.nih.gov/2685488 2685488]|[https://pubmed.ncbi.nlm.nih.gov/9328574 9328574]|[https://pubmed.ncbi.nlm.nih.gov/4055789 4055789]|[https://pubmed.ncbi.nlm.nih.gov/10096568 10096568]|[https://pubmed.ncbi.nlm.nih.gov/1644805 1644805]|[https://pubmed.ncbi.nlm.nih.gov/2582447 2582447] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GTC:G74121RX|GlycoEpitope:EP0064|CID: | '''term_xref''' : GTC:G74121RX|GlycoEpitope:EP0064|CID:91852520|GlycoMotif:GGM.000093 <br> | ||
'''synonyms''' : acGD3|9-O-Acetylated GD3|9-O-Acetyl-GD3|9-O-Ac-GD3|CD60b <br> | '''synonyms''' : acGD3|9-O-Acetylated GD3|9-O-Acetyl-GD3|9-O-Ac-GD3|CD60b <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 463: | Line 463: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31411667 31411667]|[https://pubmed.ncbi.nlm.nih.gov/27936566 27936566]|[https://pubmed.ncbi.nlm.nih.gov/2509478 2509478]|[https://pubmed.ncbi.nlm.nih.gov/10049046 10049046]|[https://pubmed.ncbi.nlm.nih.gov/1826463 1826463] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31411667 31411667]|[https://pubmed.ncbi.nlm.nih.gov/27936566 27936566]|[https://pubmed.ncbi.nlm.nih.gov/2509478 2509478]|[https://pubmed.ncbi.nlm.nih.gov/10049046 10049046]|[https://pubmed.ncbi.nlm.nih.gov/1826463 1826463] <br> | ||
'''definition''' : N-acetyl-9-O-acetyl-alpha-neuraminic acid is a member of the class of N-acetylneuraminic acids that is alpha-neuraminic acid which has acetylated on N-5 and O-9. It has functional parent alpha-neuraminic acid.[CHEBI:84941] <br> | '''definition''' : N-acetyl-9-O-acetyl-alpha-neuraminic acid is a member of the class of N-acetylneuraminic acids that is alpha-neuraminic acid which has acetylated on N-5 and O-9. It has functional parent alpha-neuraminic acid.[CHEBI:84941] <br> | ||
'''term_xref''' : GTC:G47325QT|GlycoEpitope:EP0065|CID: | '''term_xref''' : GTC:G47325QT|GlycoEpitope:EP0065|CID:13991612|CHEBI:84941 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 478: | Line 478: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27196314 27196314]|[https://pubmed.ncbi.nlm.nih.gov/6583282 6583282]|[https://pubmed.ncbi.nlm.nih.gov/8340255 8340255]|[https://pubmed.ncbi.nlm.nih.gov/18701592 18701592]|[https://pubmed.ncbi.nlm.nih.gov/21901093 21901093]|[https://pubmed.ncbi.nlm.nih.gov/2413709 2413709]|[https://pubmed.ncbi.nlm.nih.gov/8036794 8036794]|[https://pubmed.ncbi.nlm.nih.gov/1615929 1615929]|[https://pubmed.ncbi.nlm.nih.gov/3285099 3285099] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27196314 27196314]|[https://pubmed.ncbi.nlm.nih.gov/6583282 6583282]|[https://pubmed.ncbi.nlm.nih.gov/8340255 8340255]|[https://pubmed.ncbi.nlm.nih.gov/18701592 18701592]|[https://pubmed.ncbi.nlm.nih.gov/21901093 21901093]|[https://pubmed.ncbi.nlm.nih.gov/2413709 2413709]|[https://pubmed.ncbi.nlm.nih.gov/8036794 8036794]|[https://pubmed.ncbi.nlm.nih.gov/1615929 1615929]|[https://pubmed.ncbi.nlm.nih.gov/3285099 3285099] <br> | ||
'''definition''' : A branched amino tetrasaccharide comprising N-acetyl-β-D-glucosamine at the reducing end with a N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl moiety attached at the 4-position.[CHEBI:62486] <br> | '''definition''' : A branched amino tetrasaccharide comprising N-acetyl-β-D-glucosamine at the reducing end with a N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl moiety attached at the 4-position.[CHEBI:62486] <br> | ||
'''term_xref''' : GTC:G74353FF|CID: | '''term_xref''' : GTC:G74353FF|CID:53262376|GlycoEpitope:EP0257|CHEBI:62486|GlycoMotif:GGM.000038 <br> | ||
'''synonyms''' : A Type 2|Blood group A type 2 chain<br> | '''synonyms''' : A Type 2|Blood group A type 2 chain<br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 490: | Line 490: | ||
'''glycan_dictionary_accession''' : GSD000016 <br> | '''glycan_dictionary_accession''' : GSD000016 <br> | ||
'''glytoucan_accession ''' : [https://www.glygen.org/glycan/G24432YB G24432YB] <br> | '''glytoucan_accession ''' : [https://www.glygen.org/glycan/G24432YB G24432YB] <br> | ||
'''term_in_sentence''' : Therefore, alpha-gal antigen might be eliminated after a prolonged culture, when using human cells.[PMID: | '''term_in_sentence''' : Therefore, alpha-gal antigen might be eliminated after a prolonged culture, when using human cells.[PMID:[https://pubmed.ncbi.nlm.nih.gov/31267683 31267683]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/31267683 31267683]|[https://pubmed.ncbi.nlm.nih.gov/29319188 29319188]|[https://pubmed.ncbi.nlm.nih.gov/29481481 29481481]|[https://pubmed.ncbi.nlm.nih.gov/26140655 26140655]|[https://pubmed.ncbi.nlm.nih.gov/30337555 30337555]|[https://pubmed.ncbi.nlm.nih.gov/29235434 29235434]|[https://pubmed.ncbi.nlm.nih.gov/22909134 22909134]|[https://pubmed.ncbi.nlm.nih.gov/28280265 28280265]|[https://pubmed.ncbi.nlm.nih.gov/7532618 7532618]|[https://pubmed.ncbi.nlm.nih.gov/23390540 23390540]|[https://pubmed.ncbi.nlm.nih.gov/22808845 22808845]|[https://pubmed.ncbi.nlm.nih.gov/29898796 29898796]|[https://pubmed.ncbi.nlm.nih.gov/22262104 22262104]| [https://pubmed.ncbi.nlm.nih.gov/31267683 31267683]|[https://pubmed.ncbi.nlm.nih.gov/25430953 25430953]|[https://pubmed.ncbi.nlm.nih.gov/22993330 22993330]|[https://pubmed.ncbi.nlm.nih.gov/23578170 23578170]|[https://pubmed.ncbi.nlm.nih.gov/21043478 21043478]|[https://pubmed.ncbi.nlm.nih.gov/28294277 28294277]|[https://pubmed.ncbi.nlm.nih.gov/27696820 27696820]|[https://pubmed.ncbi.nlm.nih.gov/15814276 15814276]|[https://pubmed.ncbi.nlm.nih.gov/17991149 17991149]|[https://pubmed.ncbi.nlm.nih.gov/25577211 25577211]|[https://pubmed.ncbi.nlm.nih.gov/30578545 30578545]|[https://pubmed.ncbi.nlm.nih.gov/19895316 19895316]|[https://pubmed.ncbi.nlm.nih.gov/28068870 28068870]|[https://pubmed.ncbi.nlm.nih.gov/18546155 18546155]|[https://pubmed.ncbi.nlm.nih.gov/32907757 32907757]|[https://pubmed.ncbi.nlm.nih.gov/26485996 26485996]|[https://pubmed.ncbi.nlm.nih.gov/9771839 9771839]|[https://pubmed.ncbi.nlm.nih.gov/12042247 12042247]|[https://pubmed.ncbi.nlm.nih.gov/27567275 27567275]|[https://pubmed.ncbi.nlm.nih.gov/12131678 12131678]|[https://pubmed.ncbi.nlm.nih.gov/23114154 23114154]|[https://pubmed.ncbi.nlm.nih.gov/19184002 19184002]|[https://pubmed.ncbi.nlm.nih.gov/29577591 29577591]|[https://pubmed.ncbi.nlm.nih.gov/29806570 29806570]|[https://pubmed.ncbi.nlm.nih.gov/15638815 15638815]|[https://pubmed.ncbi.nlm.nih.gov/21118731 21118731] <br> | ||
'''definition''' : A glycosylgalactose that consists of β-D-galactose having an α-D-galactosyl residue at the 3-position.[CHEBI:62330] <br> | '''definition''' : A glycosylgalactose that consists of β-D-galactose having an α-D-galactosyl residue at the 3-position.[CHEBI:62330] <br> | ||
'''term_xref''' : GTC:G24432YB|GlycoMotif:GGM.000015|CID: | '''term_xref''' : GTC:G24432YB|GlycoMotif:GGM.000015|CID:52939789|CHEBI:62330 <br> | ||
'''synonyms''' : a-Gal antigen <br> | '''synonyms''' : a-Gal antigen <br> | ||
'''function''' : Has role as a carbohydrate allergen, epitope or an antigen.[CHEBI:62330] <br> | '''function''' : Has role as a carbohydrate allergen, epitope or an antigen.[CHEBI:62330] <br> | ||
| Line 521: | Line 521: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : Typical crystallizable fragment (Fc) glycans attached to the CH2 domain in therapeutic monoclonal antibodies (mAbs) are core-fucosylated and asialo-biantennary complex-type glycans, e.g., G2F (full galactosylation), G1aF (terminal galactosylation on the Man α1-6 arm), G1bF (terminal galactosylation on the Man α1-3 arm), and G0F (non-galactosylation).[PMID:[https://pubmed.ncbi.nlm.nih.gov/30990348 30990348]] <br> | '''term_in_sentence''' : Typical crystallizable fragment (Fc) glycans attached to the CH2 domain in therapeutic monoclonal antibodies (mAbs) are core-fucosylated and asialo-biantennary complex-type glycans, e.g., G2F (full galactosylation), G1aF (terminal galactosylation on the Man α1-6 arm), G1bF (terminal galactosylation on the Man α1-3 arm), and G0F (non-galactosylation).[PMID:[https://pubmed.ncbi.nlm.nih.gov/30990348 30990348]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30990348 30990348]|[https://pubmed.ncbi.nlm.nih.gov/17645671 17645671]|[https://pubmed.ncbi.nlm.nih.gov/20959391 20959391]|[https://pubmed.ncbi.nlm.nih.gov/18615430 18615430]|[https://pubmed.ncbi.nlm.nih.gov/16945378 16945378]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/30990348 30990348]|[https://pubmed.ncbi.nlm.nih.gov/17645671 17645671]|[https://pubmed.ncbi.nlm.nih.gov/20959391 20959391]|[https://pubmed.ncbi.nlm.nih.gov/18615430 18615430]|[https://pubmed.ncbi.nlm.nih.gov/16945378 16945378]|[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054]|[https://pubmed.ncbi.nlm.nih.gov/3084472 3084472]|[https://pubmed.ncbi.nlm.nih.gov/2386787 2386787] |[https://pubmed.ncbi.nlm.nih.gov/22911097 22911097]|[https://pubmed.ncbi.nlm.nih.gov/24692304 24692304]|[https://pubmed.ncbi.nlm.nih.gov/17013932 17013932]|[https://pubmed.ncbi.nlm.nih.gov/7513972 7513972]| [https://pubmed.ncbi.nlm.nih.gov/6626573 6626573]|[https://pubmed.ncbi.nlm.nih.gov/10835250 10835250]|[https://pubmed.ncbi.nlm.nih.gov/9684342 9684342] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
| Line 539: | Line 539: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29106974 29106974]|[https://pubmed.ncbi.nlm.nih.gov/3418980 3418980]|[https://pubmed.ncbi.nlm.nih.gov/26975993 26975993]|[https://pubmed.ncbi.nlm.nih.gov/8613364 8613364]|[https://pubmed.ncbi.nlm.nih.gov/9288228 9288228]|[https://pubmed.ncbi.nlm.nih.gov/26710925 26710925]|[https://pubmed.ncbi.nlm.nih.gov/24922516 24922516]|[https://pubmed.ncbi.nlm.nih.gov/6839313 6839313]|[https://pubmed.ncbi.nlm.nih.gov/1828259 1828259]|[https://pubmed.ncbi.nlm.nih.gov/2581667 2581667]|[https://pubmed.ncbi.nlm.nih.gov/8210226 8210226]|[https://pubmed.ncbi.nlm.nih.gov/25062498 25062498]|[https://pubmed.ncbi.nlm.nih.gov/9671150 9671150]|[https://pubmed.ncbi.nlm.nih.gov/10377092 10377092]|[https://pubmed.ncbi.nlm.nih.gov/6171919 6171919]|[https://pubmed.ncbi.nlm.nih.gov/3093429 3093429]|[https://pubmed.ncbi.nlm.nih.gov/6652964 6652964]|[https://pubmed.ncbi.nlm.nih.gov/3124753 3124753]|[https://pubmed.ncbi.nlm.nih.gov/8905612 8905612]|[https://pubmed.ncbi.nlm.nih.gov/18788941 18788941]|[https://pubmed.ncbi.nlm.nih.gov/1467432 1467432]|[https://pubmed.ncbi.nlm.nih.gov/8225593 8225593]|[https://pubmed.ncbi.nlm.nih.gov/2083955 2083955]|[https://pubmed.ncbi.nlm.nih.gov/6171918 6171918]|[https://pubmed.ncbi.nlm.nih.gov/7806377 7806377]|[https://pubmed.ncbi.nlm.nih.gov/1802483 1802483]|[https://pubmed.ncbi.nlm.nih.gov/7927723 7927723]|[https://pubmed.ncbi.nlm.nih.gov/9209156 9209156]|[https://pubmed.ncbi.nlm.nih.gov/21174147 21174147]|[https://pubmed.ncbi.nlm.nih.gov/2584393 2584393]|[https://pubmed.ncbi.nlm.nih.gov/12137200 12137200]|[https://pubmed.ncbi.nlm.nih.gov/6175621 6175621]|[https://pubmed.ncbi.nlm.nih.gov/2936802 2936802]|[https://pubmed.ncbi.nlm.nih.gov/8610366 8610366]|[https://pubmed.ncbi.nlm.nih.gov/21490162 21490162]|[https://pubmed.ncbi.nlm.nih.gov/1548508 1548508]|[https://pubmed.ncbi.nlm.nih.gov/3486908 3486908]|[https://pubmed.ncbi.nlm.nih.gov/26453755 26453755]|[https://pubmed.ncbi.nlm.nih.gov/7910939 7910939]|[https://pubmed.ncbi.nlm.nih.gov/3756909 3756909]|[https://pubmed.ncbi.nlm.nih.gov/1639356 1639356]|[https://pubmed.ncbi.nlm.nih.gov/3259967 3259967]|[https://pubmed.ncbi.nlm.nih.gov/2443562 2443562]|[https://pubmed.ncbi.nlm.nih.gov/3112077 3112077]|[https://pubmed.ncbi.nlm.nih.gov/2572647 2572647]|[https://pubmed.ncbi.nlm.nih.gov/25137483 25137483]|[https://pubmed.ncbi.nlm.nih.gov/2168971 2168971]|[https://pubmed.ncbi.nlm.nih.gov/6950172 6950172] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29106974 29106974]|[https://pubmed.ncbi.nlm.nih.gov/3418980 3418980]|[https://pubmed.ncbi.nlm.nih.gov/26975993 26975993]|[https://pubmed.ncbi.nlm.nih.gov/8613364 8613364]|[https://pubmed.ncbi.nlm.nih.gov/9288228 9288228]|[https://pubmed.ncbi.nlm.nih.gov/26710925 26710925]|[https://pubmed.ncbi.nlm.nih.gov/24922516 24922516]|[https://pubmed.ncbi.nlm.nih.gov/6839313 6839313]|[https://pubmed.ncbi.nlm.nih.gov/1828259 1828259]|[https://pubmed.ncbi.nlm.nih.gov/2581667 2581667]|[https://pubmed.ncbi.nlm.nih.gov/8210226 8210226]|[https://pubmed.ncbi.nlm.nih.gov/25062498 25062498]|[https://pubmed.ncbi.nlm.nih.gov/9671150 9671150]|[https://pubmed.ncbi.nlm.nih.gov/10377092 10377092]|[https://pubmed.ncbi.nlm.nih.gov/6171919 6171919]|[https://pubmed.ncbi.nlm.nih.gov/3093429 3093429]|[https://pubmed.ncbi.nlm.nih.gov/6652964 6652964]|[https://pubmed.ncbi.nlm.nih.gov/3124753 3124753]|[https://pubmed.ncbi.nlm.nih.gov/8905612 8905612]|[https://pubmed.ncbi.nlm.nih.gov/18788941 18788941]|[https://pubmed.ncbi.nlm.nih.gov/1467432 1467432]|[https://pubmed.ncbi.nlm.nih.gov/8225593 8225593]|[https://pubmed.ncbi.nlm.nih.gov/2083955 2083955]|[https://pubmed.ncbi.nlm.nih.gov/6171918 6171918]|[https://pubmed.ncbi.nlm.nih.gov/7806377 7806377]|[https://pubmed.ncbi.nlm.nih.gov/1802483 1802483]|[https://pubmed.ncbi.nlm.nih.gov/7927723 7927723]|[https://pubmed.ncbi.nlm.nih.gov/9209156 9209156]|[https://pubmed.ncbi.nlm.nih.gov/21174147 21174147]|[https://pubmed.ncbi.nlm.nih.gov/2584393 2584393]|[https://pubmed.ncbi.nlm.nih.gov/12137200 12137200]|[https://pubmed.ncbi.nlm.nih.gov/6175621 6175621]|[https://pubmed.ncbi.nlm.nih.gov/2936802 2936802]|[https://pubmed.ncbi.nlm.nih.gov/8610366 8610366]|[https://pubmed.ncbi.nlm.nih.gov/21490162 21490162]|[https://pubmed.ncbi.nlm.nih.gov/1548508 1548508]|[https://pubmed.ncbi.nlm.nih.gov/3486908 3486908]|[https://pubmed.ncbi.nlm.nih.gov/26453755 26453755]|[https://pubmed.ncbi.nlm.nih.gov/7910939 7910939]|[https://pubmed.ncbi.nlm.nih.gov/3756909 3756909]|[https://pubmed.ncbi.nlm.nih.gov/1639356 1639356]|[https://pubmed.ncbi.nlm.nih.gov/3259967 3259967]|[https://pubmed.ncbi.nlm.nih.gov/2443562 2443562]|[https://pubmed.ncbi.nlm.nih.gov/3112077 3112077]|[https://pubmed.ncbi.nlm.nih.gov/2572647 2572647]|[https://pubmed.ncbi.nlm.nih.gov/25137483 25137483]|[https://pubmed.ncbi.nlm.nih.gov/2168971 2168971]|[https://pubmed.ncbi.nlm.nih.gov/6950172 6950172] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoMotif:GGM.000099|GTC:G21856LC|CID: | '''term_xref''' : GlycoMotif:GGM.000099|GTC:G21856LC|CID:10169040|GlycoEpitope:EP0047|CHEBI:59216 <br> | ||
'''synonyms''' : as-GM1|GA-1|Gangliotetraosylceramide|GgO4|Gg4|Asialo-GM1a|ganglio-N-tetraosylceramide <br> | '''synonyms''' : as-GM1|GA-1|Gangliotetraosylceramide|GgO4|Gg4|Asialo-GM1a|ganglio-N-tetraosylceramide <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 554: | Line 554: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27956354 27956354]|[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/27956354 27956354]|[https://pubmed.ncbi.nlm.nih.gov/22929125 22929125] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoMotif:GGM.000104|GTC:G72557NR|CID: | '''term_xref''' : GlycoMotif:GGM.000104|GTC:G72557NR|CID: 91847819|KEGG:G01803|CHEBI:153361 <br> | ||
'''synonyms''' : B-GD1b <br> | '''synonyms''' : B-GD1b <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 569: | Line 569: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3680254 3680254] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/3680254 3680254] <br> | ||
'''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-5-hydroxy-4-[(2R,3R,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:147588] <br> | '''definition''' : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-5-hydroxy-4-[(2R,3R,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:147588] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000102|GTC:G11485ID|CID: | '''term_xref''' : GlycoMotif:GGM.000102|GTC:G11485ID|CID:91853157|CHEBI:147588|SugarBind_Ligand:181 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 581: | Line 581: | ||
'''glycan_dictionary_accession''' : GSD000022 <br> | '''glycan_dictionary_accession''' : GSD000022 <br> | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : We found an efficient isopropylidenation reaction that selectively protects the terminal Gal-3,4-OH of a biantennary complex-type nonasaccharide isolated from a natural source.[PMID: | '''term_in_sentence''' : We found an efficient isopropylidenation reaction that selectively protects the terminal Gal-3,4-OH of a biantennary complex-type nonasaccharide isolated from a natural source.[PMID: [https://pubmed.ncbi.nlm.nih.gov/29249147 29249147]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/29249147 29249147]| [https://pubmed.ncbi.nlm.nih.gov/24991291 24991291]|[https://pubmed.ncbi.nlm.nih.gov/29409839 29409839]| [https://pubmed.ncbi.nlm.nih.gov/30325416 30325416]|[https://pubmed.ncbi.nlm.nih.gov/18083109 18083109]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/16715395 16715395]| [https://pubmed.ncbi.nlm.nih.gov/12634321 12634321]|[https://pubmed.ncbi.nlm.nih.gov/24211369 24211369]|[https://pubmed.ncbi.nlm.nih.gov/23115267 23115267]|[https://pubmed.ncbi.nlm.nih.gov/31907993 31907993]| [https://pubmed.ncbi.nlm.nih.gov/23360551 23360551]|[https://pubmed.ncbi.nlm.nih.gov/20861009 20861009]| [https://pubmed.ncbi.nlm.nih.gov/33142198 33142198]|[https://pubmed.ncbi.nlm.nih.gov/11442281 11442281]|[https://pubmed.ncbi.nlm.nih.gov/18687680 18687680]|[https://pubmed.ncbi.nlm.nih.gov/15680603 15680603]|[https://pubmed.ncbi.nlm.nih.gov/31888963 31888963]| [https://pubmed.ncbi.nlm.nih.gov/14686925 14686925] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]]| [https://pubmed.ncbi.nlm.nih.gov/15819890 15819890]| [https://pubmed.ncbi.nlm.nih.gov/22530754 22530754] [https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]]|[https://pubmed.ncbi.nlm.nih.gov/22098756 22098756]|[https://pubmed.ncbi.nlm.nih.gov/9346821 9346821]|[https://pubmed.ncbi.nlm.nih.gov/19341309 19341309]|[https://pubmed.ncbi.nlm.nih.gov/18529007 18529007]| [https://pubmed.ncbi.nlm.nih.gov/20580347 20580347]|[https://pubmed.ncbi.nlm.nih.gov/11784152 11784152]|[https://pubmed.ncbi.nlm.nih.gov/7773775 7773775]|[https://pubmed.ncbi.nlm.nih.gov/10913832 10913832]|[https://pubmed.ncbi.nlm.nih.gov/8547276 8547276]|[https://pubmed.ncbi.nlm.nih.gov/10463590 10463590]|[https://pubmed.ncbi.nlm.nih.gov/9404657 9404657]|[https://pubmed.ncbi.nlm.nih.gov/30525457 30525457]|[https://pubmed.ncbi.nlm.nih.gov/15316280 15316280]|[https://pubmed.ncbi.nlm.nih.gov/8068637 8068637]|[https://pubmed.ncbi.nlm.nih.gov/3881425 3881425]| [https://pubmed.ncbi.nlm.nih.gov/6425277 6425277]|[https://pubmed.ncbi.nlm.nih.gov/8576139 8576139]|[https://pubmed.ncbi.nlm.nih.gov/29956878 29956878]|[https://pubmed.ncbi.nlm.nih.gov/1576211 1576211]|[https://pubmed.ncbi.nlm.nih.gov/11129583 11129583]|[https://pubmed.ncbi.nlm.nih.gov/30421263 30421263]|[https://pubmed.ncbi.nlm.nih.gov/8069634 8069634]|[https://pubmed.ncbi.nlm.nih.gov/30973186 30973186]| [https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]| [https://pubmed.ncbi.nlm.nih.gov/21612260 21612260]|[https://pubmed.ncbi.nlm.nih.gov/29806066 29806066]|[https://pubmed.ncbi.nlm.nih.gov/29443078 29443078] <br> | ||
'''definition''' : Type of N-linked glycan in which two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br> | '''definition''' : Type of N-linked glycan in which two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:[https://www.ncbi.nlm.nih.gov/books/NBK453019/ Glossary]] <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
| Line 597: | Line 597: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : The crystal structure of Pterocarpus angolensis lectin is determined in its ligand-free state, in complex with the fucosylated biantennary complex type decasaccharide NA2F, and in complex with a series of smaller oligosaccharide constituents of NA2F.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]] <br> | '''term_in_sentence''' : The crystal structure of Pterocarpus angolensis lectin is determined in its ligand-free state, in complex with the fucosylated biantennary complex type decasaccharide NA2F, and in complex with a series of smaller oligosaccharide constituents of NA2F.[PMID:[https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]|[https://pubmed.ncbi.nlm.nih.gov/3731182 3731182]|[https://pubmed.ncbi.nlm.nih.gov/26747427 26747427]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/16704415 16704415]|[https://pubmed.ncbi.nlm.nih.gov/3731182 3731182]|[https://pubmed.ncbi.nlm.nih.gov/26747427 26747427]| [https://pubmed.ncbi.nlm.nih.gov/32597008 32597008]|[https://pubmed.ncbi.nlm.nih.gov/6626573 6626573]|[https://pubmed.ncbi.nlm.nih.gov/29249147 29249147]|[https://pubmed.ncbi.nlm.nih.gov/28597152 28597152]|[https://pubmed.ncbi.nlm.nih.gov/25045879 25045879]|[https://pubmed.ncbi.nlm.nih.gov/30325416 30325416]|[https://pubmed.ncbi.nlm.nih.gov/12634321 12634321]|[https://pubmed.ncbi.nlm.nih.gov/31888963 31888963]|[https://pubmed.ncbi.nlm.nih.gov/26926155 26926155]|[https://pubmed.ncbi.nlm.nih.gov/23360551 23360551]|[https://pubmed.ncbi.nlm.nih.gov/33142198 33142198]|[https://pubmed.ncbi.nlm.nih.gov/9404657 9404657]|[https://pubmed.ncbi.nlm.nih.gov/29956878 29956878]| [https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]|[https://pubmed.ncbi.nlm.nih.gov/18687680 18687680]|[https://pubmed.ncbi.nlm.nih.gov/11784152 11784152]|[https://pubmed.ncbi.nlm.nih.gov/7773775 7773775]|[https://pubmed.ncbi.nlm.nih.gov/[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754] [https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]]|[https://pubmed.ncbi.nlm.nih.gov/20580347 20580347]|[https://pubmed.ncbi.nlm.nih.gov/22098756 22098756]|[https://pubmed.ncbi.nlm.nih.gov/21612260 21612260]|[https://pubmed.ncbi.nlm.nih.gov/6425277 6425277]|[https://pubmed.ncbi.nlm.nih.gov/7691595 7691595]|[https://pubmed.ncbi.nlm.nih.gov/26780731 26780731]|[https://pubmed.ncbi.nlm.nih.gov/16285669 16285669]|[https://pubmed.ncbi.nlm.nih.gov/15819890 15819890]|[https://pubmed.ncbi.nlm.nih.gov/3924097 3924097]|[https://pubmed.ncbi.nlm.nih.gov/30448401 30448401]|[https://pubmed.ncbi.nlm.nih.gov/8547276 8547276]|[https://pubmed.ncbi.nlm.nih.gov/17049014 17049014]|[https://pubmed.ncbi.nlm.nih.gov/29408873 29408873] <br> | ||
'''definition''' : A complex N-glycan that has two branches attached to the non-reducing terminal Man residues of the trimannosyl core. . Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [CHEBI:156251] <br> | '''definition''' : A complex N-glycan that has two branches attached to the non-reducing terminal Man residues of the trimannosyl core. . Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [CHEBI:156251] <br> | ||
'''term_xref''' : CHEBI:156251 <br> | '''term_xref''' : CHEBI:156251 <br> | ||
| Line 612: | Line 612: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : The presence of a bisecting GlcNAc and the occurrence of alpha 2-6-linked Neu5Ac in the most abundant N-glycans, are new features for hCG-beta.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1374031 1374031]] <br> | '''term_in_sentence''' : The presence of a bisecting GlcNAc and the occurrence of alpha 2-6-linked Neu5Ac in the most abundant N-glycans, are new features for hCG-beta.[PMID:[https://pubmed.ncbi.nlm.nih.gov/1374031 1374031]] <br> | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1374031 1374031]|[https://pubmed.ncbi.nlm.nih.gov/29909448 29909448]|[https://pubmed.ncbi.nlm.nih.gov/29274553 29274553]|[https://pubmed.ncbi.nlm.nih.gov/32719771 32719771]|[https://pubmed.ncbi.nlm.nih.gov/22476631 22476631]|[https://pubmed.ncbi.nlm.nih.gov/31375533 31375533]|[https://pubmed.ncbi.nlm.nih.gov/26467158 26467158]|[https://pubmed.ncbi.nlm.nih.gov/27429195 27429195]|[https://pubmed.ncbi.nlm.nih.gov/20816221 20816221]|[https://pubmed.ncbi.nlm.nih.gov/26109616 26109616]|[https://pubmed.ncbi.nlm.nih.gov/30542567 30542567]|[https://pubmed.ncbi.nlm.nih.gov/30144245 30144245]|[https://pubmed.ncbi.nlm.nih.gov/25727145 25727145]|[https://pubmed.ncbi.nlm.nih.gov/29593568 29593568]|[https://pubmed.ncbi.nlm.nih.gov/32612952 32612952]|[https://pubmed.ncbi.nlm.nih.gov/9006930 9006930]|[https://pubmed.ncbi.nlm.nih.gov/19508951 19508951]|[https://pubmed.ncbi.nlm.nih.gov/16000695 16000695]| | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/1374031 1374031]|[https://pubmed.ncbi.nlm.nih.gov/29909448 29909448]|[https://pubmed.ncbi.nlm.nih.gov/29274553 29274553]|[https://pubmed.ncbi.nlm.nih.gov/32719771 32719771]|[https://pubmed.ncbi.nlm.nih.gov/22476631 22476631]|[https://pubmed.ncbi.nlm.nih.gov/31375533 31375533]|[https://pubmed.ncbi.nlm.nih.gov/26467158 26467158]|[https://pubmed.ncbi.nlm.nih.gov/27429195 27429195]|[https://pubmed.ncbi.nlm.nih.gov/20816221 20816221]|[https://pubmed.ncbi.nlm.nih.gov/26109616 26109616]|[https://pubmed.ncbi.nlm.nih.gov/30542567 30542567]|[https://pubmed.ncbi.nlm.nih.gov/30144245 30144245]|[https://pubmed.ncbi.nlm.nih.gov/25727145 25727145]|[https://pubmed.ncbi.nlm.nih.gov/29593568 29593568]|[https://pubmed.ncbi.nlm.nih.gov/32612952 32612952]|[https://pubmed.ncbi.nlm.nih.gov/9006930 9006930]|[https://pubmed.ncbi.nlm.nih.gov/19508951 19508951]|[https://pubmed.ncbi.nlm.nih.gov/16000695 16000695]|[https://pubmed.ncbi.nlm.nih.gov/32597008 32597008]|[https://pubmed.ncbi.nlm.nih.gov/19053837 19053837]|[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]|[https://pubmed.ncbi.nlm.nih.gov/30405631 30405631]|[https://pubmed.ncbi.nlm.nih.gov/19940114 19940114]|[https://pubmed.ncbi.nlm.nih.gov/32719549 32719549]|[https://pubmed.ncbi.nlm.nih.gov/9560299 9560299]|[https://pubmed.ncbi.nlm.nih.gov/29655002 29655002]|[https://pubmed.ncbi.nlm.nih.gov/10589784 10589784]|[https://pubmed.ncbi.nlm.nih.gov/29959030 29959030]|[https://pubmed.ncbi.nlm.nih.gov/20661133 20661133]|[https://pubmed.ncbi.nlm.nih.gov/9061364 9061364]|[https://pubmed.ncbi.nlm.nih.gov/31065629 31065629]|[https://pubmed.ncbi.nlm.nih.gov/20395209 20395209]|[https://pubmed.ncbi.nlm.nih.gov/29549127 29549127]|[https://pubmed.ncbi.nlm.nih.gov/30305426 30305426]|[https://pubmed.ncbi.nlm.nih.gov/29632412 29632412]|[https://pubmed.ncbi.nlm.nih.gov/24108122 24108122]|[https://pubmed.ncbi.nlm.nih.gov/24282611 24282611]|[https://pubmed.ncbi.nlm.nih.gov/27821068 27821068]|[https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]|[https://pubmed.ncbi.nlm.nih.gov/10816579 10816579]|[https://pubmed.ncbi.nlm.nih.gov/25032906 25032906]|[https://pubmed.ncbi.nlm.nih.gov/30025558 30025558]|[https://pubmed.ncbi.nlm.nih.gov/9661906 9661906]|[https://pubmed.ncbi.nlm.nih.gov/8542600 8542600]|[https://pubmed.ncbi.nlm.nih.gov/31585439 31585439]|[https://pubmed.ncbi.nlm.nih.gov/29699572 29699572]|[https://pubmed.ncbi.nlm.nih.gov/27443163 27443163]|[https://pubmed.ncbi.nlm.nih.gov/30315103 30315103]|[https://pubmed.ncbi.nlm.nih.gov/23808883 23808883]|[https://pubmed.ncbi.nlm.nih.gov/18812317 18812317]|[https://pubmed.ncbi.nlm.nih.gov/19776078 19776078] <br> | ||
'''definition''' : The bisecting GlcNAc is a modification of hybrid or complex N-linked glycans in which a single GlcNAc is added to the 3 position of the b-linked Man found in the trimannosyl core structure. The modification is catalyzed by beta 1,4-N-acetylglucosaminyltransferase III (GlcNAcT-III) or MGAT3 (E.C. 2.4.1.144). The addition of a bisecting GlcNAc on a hybrid or trimmed hybrid glycan prevents the subsequent action of N-glycan branching glycosyltransferases GlcNAcT-IV and GlcNAcT-V, but GlcNAcT3 can add a bisecting GlcNAc to the products of these enzymes. [PMID: [https://pubmed.ncbi.nlm.nih.gov/22476631 22476631]] <br> | '''definition''' : The bisecting GlcNAc is a modification of hybrid or complex N-linked glycans in which a single GlcNAc is added to the 3 position of the b-linked Man found in the trimannosyl core structure. The modification is catalyzed by beta 1,4-N-acetylglucosaminyltransferase III (GlcNAcT-III) or MGAT3 (E.C. 2.4.1.144). The addition of a bisecting GlcNAc on a hybrid or trimmed hybrid glycan prevents the subsequent action of N-glycan branching glycosyltransferases GlcNAcT-IV and GlcNAcT-V, but GlcNAcT3 can add a bisecting GlcNAc to the products of these enzymes. [PMID: [https://pubmed.ncbi.nlm.nih.gov/22476631 22476631]] <br> | ||
'''term_xref''' : SID:163312364|KEGG:G13066<br> | '''term_xref''' : SID:163312364|KEGG:G13066<br> | ||
| Line 627: | Line 627: | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F, compared with elution positions of standard oligosaccharide structures, coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate, confirming earlier work published by this laboratory. <br> | '''term_in_sentence''' : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F, compared with elution positions of standard oligosaccharide structures, coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate, confirming earlier work published by this laboratory. <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]|[https://pubmed.ncbi.nlm.nih.gov/2065054 2065054] <br> | ||
'''definition''' : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae. <br> | '''definition''' : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
| Line 641: | Line 641: | ||
'''glycan_dictionary_accession''' : GSD000026 <br> | '''glycan_dictionary_accession''' : GSD000026 <br> | ||
'''glytoucan_accession ''' : <br> | '''glytoucan_accession ''' : <br> | ||
'''term_in_sentence''' : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F , compared with elution positions of standard oligosaccharide structures , coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate , confirming earlier work published by this laboratory.[PMID: | '''term_in_sentence''' : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F , compared with elution positions of standard oligosaccharide structures , coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate , confirming earlier work published by this laboratory.[PMID: [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]] <br> | ||
'''publication''' : | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2386787 2386787]|[https://pubmed.ncbi.nlm.nih.gov/26966183 26966183] <br> | ||
'''definition''' : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae. <br> | '''definition''' : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae. <br> | ||
'''term_xref''' : <br> | '''term_xref''' : <br> | ||
| Line 659: | Line 659: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2417620 2417620] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/2417620 2417620] <br> | ||
'''definition''' : A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 3 of the glucosamine. Corresponds to a partial structure of blood group A type 2 oligosaccharide.[CHEBI:62990] <br> | '''definition''' : A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 3 of the glucosamine. Corresponds to a partial structure of blood group A type 2 oligosaccharide.[CHEBI:62990] <br> | ||
'''term_xref''' : GlycoEpitope:EP0261|GTC:G54826OZ|CHEBI:62990|CID: | '''term_xref''' : GlycoEpitope:EP0261|GTC:G54826OZ|CHEBI:62990|CID:5289011|GlycoMotif:GGM.000039 <br> | ||
'''synonyms''' : Blood group A (type 2) (A-Ley)|Blood Group A Type 2 (difucosyl)|Blood group A (type 2) (A-Lewis Y)|A-Ley|A-Le^y <br> | '''synonyms''' : Blood group A (type 2) (A-Ley)|Blood Group A Type 2 (difucosyl)|Blood group A (type 2) (A-Lewis Y)|A-Ley|A-Le^y <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 674: | Line 674: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7800218 7800218]|[https://pubmed.ncbi.nlm.nih.gov/7521740 7521740]|[https://pubmed.ncbi.nlm.nih.gov/2458640 2458640]|[https://pubmed.ncbi.nlm.nih.gov/31283166 31283166] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/7800218 7800218]|[https://pubmed.ncbi.nlm.nih.gov/7521740 7521740]|[https://pubmed.ncbi.nlm.nih.gov/2458640 2458640]|[https://pubmed.ncbi.nlm.nih.gov/31283166 31283166] <br> | ||
'''definition''' : <br> | '''definition''' : <br> | ||
'''term_xref''' : GlycoMotif:GGM.000088|GTC:G37830TX|CID: | '''term_xref''' : GlycoMotif:GGM.000088|GTC:G37830TX|CID:91852258|KEGG:G00474|CHEBI:150159|SugarBind_Ligand:48 <br> | ||
'''synonyms''' : <br> | '''synonyms''' : <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 689: | Line 689: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19582848 19582848]|[https://pubmed.ncbi.nlm.nih.gov/7249368 7249368]|[https://pubmed.ncbi.nlm.nih.gov/8774717 8774717]|[https://pubmed.ncbi.nlm.nih.gov/2749874 2749874]|[https://pubmed.ncbi.nlm.nih.gov/28771597 28771597]|[https://pubmed.ncbi.nlm.nih.gov/30619340 30619340]|[https://pubmed.ncbi.nlm.nih.gov/2122121 2122121]|[https://pubmed.ncbi.nlm.nih.gov/11886841 11886841]|[https://pubmed.ncbi.nlm.nih.gov/2991755 2991755]|[https://pubmed.ncbi.nlm.nih.gov/12588002 12588002]|[https://pubmed.ncbi.nlm.nih.gov/3149698 3149698]|[https://pubmed.ncbi.nlm.nih.gov/7048329 7048329]|[https://pubmed.ncbi.nlm.nih.gov/7015594 7015594]|[https://pubmed.ncbi.nlm.nih.gov/10359132 10359132]|[https://pubmed.ncbi.nlm.nih.gov/8724140 8724140]|[https://pubmed.ncbi.nlm.nih.gov/1418679 1418679]|[https://pubmed.ncbi.nlm.nih.gov/1446307 1446307] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/19582848 19582848]|[https://pubmed.ncbi.nlm.nih.gov/7249368 7249368]|[https://pubmed.ncbi.nlm.nih.gov/8774717 8774717]|[https://pubmed.ncbi.nlm.nih.gov/2749874 2749874]|[https://pubmed.ncbi.nlm.nih.gov/28771597 28771597]|[https://pubmed.ncbi.nlm.nih.gov/30619340 30619340]|[https://pubmed.ncbi.nlm.nih.gov/2122121 2122121]|[https://pubmed.ncbi.nlm.nih.gov/11886841 11886841]|[https://pubmed.ncbi.nlm.nih.gov/2991755 2991755]|[https://pubmed.ncbi.nlm.nih.gov/12588002 12588002]|[https://pubmed.ncbi.nlm.nih.gov/3149698 3149698]|[https://pubmed.ncbi.nlm.nih.gov/7048329 7048329]|[https://pubmed.ncbi.nlm.nih.gov/7015594 7015594]|[https://pubmed.ncbi.nlm.nih.gov/10359132 10359132]|[https://pubmed.ncbi.nlm.nih.gov/8724140 8724140]|[https://pubmed.ncbi.nlm.nih.gov/1418679 1418679]|[https://pubmed.ncbi.nlm.nih.gov/1446307 1446307] <br> | ||
'''definition''' : A branched amino trisaccharide consisting of β-D-galactose having an α-L-fucosyl residue at the 2-position and an N-acetyl-α-D-galactosaminyl residue at the 3-position.[CHEBI:61012] <br> | '''definition''' : A branched amino trisaccharide consisting of β-D-galactose having an α-L-fucosyl residue at the 2-position and an N-acetyl-α-D-galactosaminyl residue at the 3-position.[CHEBI:61012] <br> | ||
'''term_xref''' : GlycoEpitope:EP0255|GTC:G00066MO|CID: | '''term_xref''' : GlycoEpitope:EP0255|GTC:G00066MO|CID:49852448|KEGG:G10638|CHEBI:61012 <br> | ||
'''synonyms''' : blood group A trisaccharide|blood group A type 1 trisaccharide <br> | '''synonyms''' : blood group A trisaccharide|blood group A type 1 trisaccharide <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
| Line 704: | Line 704: | ||
'''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10942408 10942408]|[https://pubmed.ncbi.nlm.nih.gov/19121199 19121199] <br> | '''publication''' : [https://pubmed.ncbi.nlm.nih.gov/10942408 10942408]|[https://pubmed.ncbi.nlm.nih.gov/19121199 19121199] <br> | ||
'''definition''' : An α-D-GalpNAc-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-D-GlcpNAc having β-configuration at the reducing end anomeric centre.[CHEBI:62485] <br> | '''definition''' : An α-D-GalpNAc-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-D-GlcpNAc having β-configuration at the reducing end anomeric centre.[CHEBI:62485] <br> | ||
'''term_xref''' : GlycoMotif:GGM.000044|GTC:G66163TI|GlycoEpitope:EP0256|CID: | '''term_xref''' : GlycoMotif:GGM.000044|GTC:G66163TI|GlycoEpitope:EP0256|CID:53262359|CHEBI:62485 <br> | ||
'''synonyms''' : Blood group A(1)|blood group A antigen type 1 <br> | '''synonyms''' : Blood group A(1)|blood group A antigen type 1 <br> | ||
'''function''' : <br> | '''function''' : <br> | ||
Revision as of 00:32, 10 April 2023
T antigen
term (main_entry) : T antigen
glycan_dictionary_accession : GSD000163
glytoucan_accession : G00031MO
term_in_sentence : Tn, sTn, and T antigen neo- or over-expression occurs in many types of cancer including gastric, colon, breast, lung, esophageal, prostate, and endometrial cancer.[PMID:27679419]
publication :723127|19505650|31527246|28113048|25868857|26731525|22994493|3849428|25589241|12709866|26615524|26136575|19671663|18551603|11160729|22261839|30758913|25681708|29113555|24998850|1654819|28039910|29206210|32404521|10555041|26517398|2446015|2998768|3026642|18812503|6092664|2153691|8709258|3009889|15109748| 12709866|31787742|27433780|26017382|24048785|26735515|9224657|26061652|29343574|[https://pubmed.ncbi.nlm.nih.gov/25681708 25681708 25681708]|23805194|26751495|22023388|15381338|8249277|3023660|25866902
definition : An amino disaccharide composed of D-galactose and N-acetyl-α-D-galactosaminyl residues in β-(1→3) linkage.[CHEBI:61820]
term_xref : GTC:G00031MO|GlycoEpitope:EP0020|CID:5288347|CHEBI:61820|GlycoMotif:GGM.000009
synonyms : TF antigen
function : accumulation Lipoprotein(a) or LDL within arterial walls in atherogenesis [GlycoEpitope:EP0020]|cancer progression (increase interaction/communication of the cells)[GlycoEpitope:EP0020]|T antigen expression in RMA lymphoma cells leads to a reduced growth of the tumor[GlycoEpitope:EP0020]|correlation with elevated Golgi pH in cancer cell (breast, colorectal cancer cells)[GlycoEpitope:EP0020]|T antigen on apical surfaces of corneal epithelial cells provide protection against rose bengal penetrance.[GlycoEpitope:EP0020]|reduction of a flexibility of the glycosidic bond and thereby favour certain glycan conformation[GlycoEpitope:EP0020]|T antigen is a target for NK cell-mediated lysis[GlycoEpitope:EP0020]|inverse relationship between T antigen expression and VWF plasma levels[GlycoEpitope:EP0020]
disease_associations : anaplastic meningioma[GlycoEpitope:EP0020]|breast cancer[GlycoEpitope:EP0020]|colorectal cancer[GlycoEpitope:EP0020]|colon cancer[GlycoEpitope:EP0020]|esophageal cancer|gastric cancer[GlycoEpitope:EP0020]|liver cancer[GlycoEpitope:EP0020]|ovarian cancer[GlycoEpitope:EP0020]|prostate cancer[GlycoEpitope:EP0020]|bladder tumor[GlycoEpitope:EP0020]|invasive pneumococcal infection (hemolytic uremic syndrome, hemolytic anemia)[GlycoEpitope:EP0020]
wikipedia :
essentials_of_glycobiology : Chapter 47
Tetraantennary
term (main_entry) : Tetraantennary
glycan_dictionary_accession : GSD000164
glytoucan_accession :
term_in_sentence : In contrast, myeloma IgE showed a higher abundance of triantennary and tetraantennary glycan structures and a low abundance of species with a bisecting N-acetylglucosamine.[PMID:24308486]
publication : 24308486|17951374|28880909|9177699|9760189|12322961|20129637|2492275|3402460|2361735|6525453|27730440|2551687|25365149|9751793|29875690|29479898|9134426|30943309|3546284|29888905|30624066|30537828|31110965|29311294|12852965|3015940|1907570|29137999|29359131|29858715|30295034|31829566|8381405|26929217|20662591|30612270|3089784|28186213|3427034|26763099|27354006|24991291|7496138|1940447|11114588|29031301|9448855|3979385|27722599|31126011|28002670|28991403|24032650|[https://pubmed.ncbi.nlm.nih.gov/15316281 15316281 15316281]|25154914|22490318|22430811|1463783|18803208|7881173|7697655|7240157|1768292
definition : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:Glossary]
term_xref :
synonyms :
function :
disease_associations :
wikipedia : https://www.wikidata.org/wiki/Q27104888
essentials_of_glycobiology :
Tetraantennary complex-type
term (main_entry) : Tetraantennary complex-type
glycan_dictionary_accession : GSD000165
glytoucan_accession :
term_in_sentence : A variety of high-mannose structures , as well as bi-, tri-, and tetraantennary complex-type carbohydrate , has been found, in relative amounts of 1-25% of the total oligosaccharides.[PMID: 1899031]
publication : 1899031|8251489|8274017|1899031| 6317691|23668542| 6088518|21495009|1457971|1783599|10988252|11425798|7522229|2574992|3730425|10200178|2939068|21584695| 7524670|7682847|2930192|1726466|9881746|11068879|6704968|2302846| 24032650|15316281|11051207|10220588|2813359|2174368|21755550|3571208|1929437|3681300|6581225|3364983|2902877|2297756|1315684|6830758|1998670
definition : Type of N-linked glycan in which four antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The four antennae are initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 2 GlcNAcs to the _6 Man (at the 2 and 6 positions) of the trimannosyl core. Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:Glossary]
term_xref : https://www.sigmaaldrich.com/technical-documents/articles/biology/glycobiology/n-glycans.html
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 10
Tetrasialylated diantennary
term (main_entry) : Tetrasialylated diantennary
glycan_dictionary_accession : GSD000166
glytoucan_accession :
term_in_sentence : A further preparation, obtained from the most anionic DEAE-cellulose fraction (peak V) or rTf contained several tetrasialylated diantennary glycans whose precise structures remain to be established in future studies.[PMID:1997323]
publication : 1997323
definition : A biantennary glycan with two GlcNAc branches linked to the core and the addition of four sialic acid residues.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
Tn antigen
term (main_entry) : Tn antigen
glycan_dictionary_accession : GSD000167
glytoucan_accession : G57321FI
term_in_sentence : Furthermore, we confirmed that LS174T cells (Tn-positive) transfected with wild-type Cosmc, thus expressing no Tn antigen, had down-regulation of H-Ras expression and subsequent inhibition of EMT process.[PMID:30637914]
publication : 27679419|31938254|30637914|24643043|31225574|21259410|31742337|28514044|33014816|28708980|27432485|33050853|26045765|27542280|24411673|27760846|30115016|1410473|29802864|29669308|29251002|32541028|31019509|1582597|2981150|10842187|29638123|22367369|10778170|1510031|19372570|20641477|16149605|15770530|27856425|23814067|28068458|32134186|8174100|10571017|27453399|1727666|23740330
definition : Tn anitigen or alpha-galnac or N-Acetylgalactosamine is an N-acetyl-D-galactosamine having alpha-configuration at the anomeric centre. It has a role as an epitope. It derives from an alpha-D-galactosamine.[CHEBI:40356,HMDB0000212]
term_xref : GTC:G57321FI|GlycoEpitope:EP0021|CID:84265|CHEBI:40356|HMDB0000212|GlycoMotif:GGM.000008
synonyms :
function : lymphatic metastasis[GlycoEpitope:EP0021]|tube formation in Drosophila development[GlycoEpitope:EP0021]|modulation of malignant phenotype (gastric carcinoma cell)[GlycoEpitope:EP0021]|correlation with tumor stage, lymphatic invasion and lymph node matastasis[GlycoEpitope:EP0021]
disease_associations : breast cancer[GlycoEpitope:EP0021]|cervical cancer[GlycoEpitope:EP0021]|colon cancer[GlycoEpitope:EP0021]|colorectal cancer[GlycoEpitope:EP0021]|fibrosarcoma[GlycoEpitope:EP0021]|gastric cancer[GlycoEpitope:EP0021]|liver cancer[GlycoEpitope:EP0021]|ovarian cancer[GlycoEpitope:EP0021]|pancreas cancer[GlycoEpitope:EP0021]|prostate cancer[GlycoEpitope:EP0021]|Tn syndorome[GlycoEpitope:EP0021]|Barrett'sesophagus[GlycoEpitope:EP0021]|Schindler/Kanzaki desease (alpha-N acetylgalactosaminidase deficiency)[GlycoEpitope:EP0021].
wikipedia :
essentials_of_glycobiology :
Triantennary
term (main_entry) : Triantennary
glycan_dictionary_accession : GSD000168
glytoucan_accession :
term_in_sentence : Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.[PMID:24992960]
publication : 24992960|27025342|29642865|29456020|26914862|26926155|26299345|28981809|18395704|2211710|23461434|18327885|15264862|22954207|9061362|16581187|26537865|3979568|28129130|7679920|8068017|7783116|3857231|20540518|1706936|2430615|8078981|2211711|6767476|3814128|2597120|7451505|8204583|20619452|10460831|1924399|6643471|31809011|30042045|2477056|7882496|2430614|2551687|2426141|2065052|28988716|31144994| 26966183|29809215
definition : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:Glossary]
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
Triantennary complex
term (main_entry) : Triantennary complex
glycan_dictionary_accession : GSD000169
glytoucan_accession :
term_in_sentence : Fucosylated biantennary complex-type and small amounts (less than 5%) of triantennary complex-type structures were identified on the glycosylated asparagine residues using sequential exoglycosidase and endoglycosidase digestions combined with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS).[PMID:9118998]
publication : 9118998|9061362|18395704|3814128|7451505|10460831|26926155|26966183|16581187|16973123|8204583|29809215|[https://pubmed.ncbi.nlm.nih.gov/11114588 11114588 11114588]|31322324|15044389|16372382|8251489|8299583|1555586|7509658|1569060|16261636
definition : A complex N-glycan that has three branches attached to the non-reducing terminal Man residues of the trimannosyl core.[CHEBI:156252] Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues.
term_xref : CHEBI:156252
synonyms : Triantennary complex-type
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 10
Triantennary N-glycans
term (main_entry) : Triantennary N-glycans
glycan_dictionary_accession : GSD000170
glytoucan_accession :
term_in_sentence : Increased expression of the high-mannose M6N2 and NeuAc3H3N3M3N2F tri-antennary N-glycans in cholangiocarcinoma.[PMID:29399163]
publication : 29399163|22325877|18439991|24873509|11454001
definition : Type of N-linked glycan in which three antennae are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). The three antennae can be be initiated by addition of 2 GlcNAcs to the _3 Man (at the 2 and 4 positions) and 1 GlcNAc to the _6 Man (at the 2 position) of the trimannosyl core or 1 on the _3 and 2 on the _6 Man (at the 2 and 6 positions). Each antenna can be extended or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:Glossary]
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
Triantennary sialylated
term (main_entry) : Triantennary sialylated
glycan_dictionary_accession : GSD000171
glytoucan_accession :
term_in_sentence : LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans.[PMID:18642129]
publication : 18642129|31964828|3979568|27936604|23681398|21538882|7579793|7613477|2223825|3539023|3674882
definition : A triantennary glycan with three GlcNAc branches linked to the core and the addition of one sialic acid residues.
term_xref :
synonyms :
function : Appears in human serotransferrin.[PMID: 3979568]
disease_associations :
wikipedia :
essentials_of_glycobiology :
Triantennary trisialylated fucosylated
term (main_entry) : Triantennary trisialylated fucosylated
glycan_dictionary_accession : GSD000172
glytoucan_accession :
term_in_sentence : Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified.[PMID:17591618]
publication : 17591618
definition : A triantennary glycan with three GlcNAc branches linked to the core and the addition of three sialic acid residues and fucose added.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
Trifucosyl Lewis b antigen
term (main_entry) : Trifucosyl Lewis b antigen
glycan_dictionary_accession : GSD000173
glytoucan_accession : G74578MX
term_in_sentence : Extended type-1 chain glycosphingolipid antigens. Isolation and characterization of trifucosyl-Leb antigen (III4V4VI2Fuc3Lc6)[PMID:1735443]
publication : 1735443
definition : N-[(2R,3R,4R,5S,6R)-4-[(2R,3R,4S,5S,6R)-4-[(2S,3R,4R,5S,6R)-3-Acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxy-6-(hydroxymethyl)-5-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]acetamide is an amino sugar.[CHEBI:153783]
term_xref : GlycoEpitope:EP0092|GTC:G74578MX|CID:91845957|CHEBI:153783
synonyms : trifucosyl-Leb antigen
function : cancer-associated antigen[GlycoEpitope: EP0092]
disease_associations : colonic cancer[GlycoEpitope: EP0092]|endometrial cancer[GlycoEpitope: EP0092]|liver cancer[GlycoEpitope: EP0092]|pancreatic cancer[GlycoEpitope: EP0092]|rectal cancer[GlycoEpitope: EP0092]
wikipedia :
essentials_of_glycobiology :
Trifucosyl lewis y
term (main_entry) : Trifucosyl lewis y
glycan_dictionary_accession : GSD000174
glytoucan_accession : G74917JX
term_in_sentence : The third, major component, common in all eight cases, has been identified as trifucosyl Ley (lactotrifucononaosylceramide, III3FucV3FucVI2FucnLc6, Structure 2 below) based on 1H NMR spectroscopy, methylation analysis, and direct-probe electron-impact mass spectrometry.[PMID:3733752]
publication : 3733752|2426269
definition : A branched heptasaccharide derivative consisting of two repeating units of β-D-Gal-(1→4)-[α-L-Fuc-(1→3)]-β-D-GlcNAc (joined by a (1→3)-linkage) with an α-L-fucosyl residue attached at the 2-position of the galactose residue at the non-reducing end.[CHEBI:61332]
term_xref : GlycoEpitope: EP0094|GTC:G74917JX|CID:50909806|CHEBI:61332
synonyms : trifucosyl Ley
function :
disease_associations : colonic adenocarcinomia[GlycoEpitope: EP0094]
wikipedia :
essentials_of_glycobiology :
Trimannosyl core
term (main_entry) : Trimannosyl core
glycan_dictionary_accession : GSD000175
glytoucan_accession :
term_in_sentence : This glycoengineered H. polymorpha strain produced glycoproteins mainly containing trimannosyl core N-glycan (Man(3)GlcNAc(2)), which is the common core backbone of various human-type N-glycans.[PMID:18320567]
publication : 18320567|27629418|26514868|26821880|2477227|6213618|31747570|29273674|31064325|1291063|28353332|1421754|29666272|11421342|15648688|28179475|28903882|27189951|9455915|22768188|9254048|8721739|2249985|22933239|25629585|24489949|2981047|11067815|1729985|1710649|16672288|2719668|19003000|23025485|22500028|10409642|1325461|23136055|23085445|21656680|22448293|22132163|1425696|20696712|18056652|15084511|18633282|15814299
definition : A glycan that constitutes the core structure common to all high-mannose, complex, or hybrid N-glycans. The trimannosyl core composition is Man3 GlcNAc2 and includes a chitobiose at the reducing terminal which is extended by a single b-linked Man residue. The b-linked Man is branched by two additional a-linked Man residues, one at the 3 position and one at the 6 position.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
Trisialylated
term (main_entry) : Trisialylated
glycan_dictionary_accession : GSD000176
glytoucan_accession :
term_in_sentence : Many (82.7%) were found to be tetraantennary N-acetyllactosamine-type (22.8% with one, 3.6% with two and 0.4% with three N-acetyllactosamine repeats) being tetrasialylated (41%), trisialylated (29.6%) and disialylated (12.2%) |HPAE-PAD and FACE analysis suggests that they are triantennary and trisialylated with core fucosylation.[PMID:8477709]
publication : 6469957|18818422|18332077|21138277|9136890|10782293|19841910|20067809|14751029|8797382|16877748|19131698|20578731|24669823|22426998|27501865|2121479|24663386|32209427|32737218|33245334|26927318|30962676|28370937|30194503|26321095|30463578|31455764|31566965|31266306|29782424|31247951|30487799|2049094| 1997323|10913832
definition : A glycan with three sialic acid components.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
Trisialylated complex-type oligosaccharide-alditols
term (main_entry) : Trisialylated complex-type oligosaccharide-alditols
glycan_dictionary_accession : GSD000177
glytoucan_accession :
term_in_sentence : The structures of the two major oligosaccharide-alditols separated by ion-exchange chromatography on a Mono Q column were investigated by means of methylation analysis, glycosidase digestion, and Smith periodate degradation, and they were assigned as typical di- and trisialylated complex-type oligosaccharide-alditols with two and three peripheral chains consisting of Gal-GlcNAc sequences , respectively.[PMID:3571205]
publication : 3571205
definition :
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
Trisialylated diantennary
term (main_entry) : Trisialylated diantennary
glycan_dictionary_accession : GSD000178
glytoucan_accession :
term_in_sentence : Determination of glycan primary structures and characterization of a new type of trisialylated diantennary glycan.[PMID:1997323]
publication : 1997323
definition : A diantennary/biantennary glycans with three sialic acid components.
term_xref :
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
Trisialylated triantennary
term (main_entry) : Trisialylated triantennary
glycan_dictionary_accession : GSD000179
glytoucan_accession :
term_in_sentence : The N-glycans are of the complex type with the core-fucosylated disialylated biantennary and trisialylated triantennary structures predominating.[PMID:8942648]
publication : 30194503|27501865|10998266|20578731|17591618|14751029|18818422|8942648|8900952
definition : A triantennry glycan with three sialic acid components.
term_xref :
synonyms :
function :
disease_associations :
essentials_of_glycobiology :
VIM-2
term (main_entry) : VIM-2
glycan_dictionary_accession : GSD000180
glytoucan_accession : G22418PV
term_in_sentence : Anti-SSEA-1 which binds to glycoconjugates with a Gal beta 1-4(fuc alpha 1-3)GlcNAc epitope and VIM-2 which binds to gangliosides with a NeuAc alpha 2-3GlcNAc beta-4(FUC alpha 1-3) GlcNAc beta 1-3Gal-epitope were used to determine the expression of their corresponding carbohydrate antigens in human leukocytes and leukemia cells.[PMID:1690317]
publication : 27834790|31523406|29978304|29575185|27326514|29029114|32450200|29432937|31906402|28739428|29298123|30976429|29091730|27770796|31330771|31138570|27154587|31542553|30519059|30590504|25880997|27490501|29981456|28559273|28193652|26638216|25897818|26238337|19553129|29644540|26242685|28487556|32622213|30248413|24762211|11451678|33169865|11897589|31479607
definition : α-Neup5Ac-(2→3)-β-D-Galp-(1→4)-β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the anomeric configuration of the N-acetyl-D-glucosamine residue at the reducing end is β.[CHEBI:85946]
term_xref : GTC:G22418PV |GlycoEpitope:EP0019|CID:91825708|CHEBI:85946|GlycoMotif:GGM.000033
synonyms :
function : CDw65 have been shown to interact with the ELAM-1 molecule on activated endothelium.[GlycoEpitope:EP0019]
disease_associations : chronic myelogenous leukemia.[GlycoEpitope:EP0019]
wikipedia :
essentials_of_glycobiology :
Terms (by Glycan Dictionary Accessions)
GSD000001
term (main_entry) : 2,6-Branched O-mannose
glycan_dictionary_accession : GSD000001
glytoucan_accession : G06953DR
term_in_sentence : Collectively, these results strongly suggest that GnT-IX may be a novel beta1,6-N-acetylglucosaminyltransferase that is responsible for the formation of the 2,6-branched structure in the brain O-mannosyl glycan.[PMID:14617637]
publication : 14617637|10469154
definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-[[(2R,3S,4S,5S,6S)-5-[(2S,3R,4R,5S,6R)-3-acetamido-5-[(2S,3R,4S,5S,6R)-4-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4,6-trihydroxyoxan-2-yl]methoxy]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:157265]
term_xref : CHEBI:157265|GlycoMotif:GGM.000056|GTC:G06953DR
synonyms : 5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→2)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)-beta-D-galacto-hexopyranosyl-(1→4)-2-acetamido-2-deoxy-beta-D-gluco-hexopyranosyl-(1→6)]-alpha-D-manno-hexopyranose|NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-2)[NeuAc(a2-3)Gal(b1-4)GlcNAc(b1-6)]a-Man
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000002
term (main_entry) : 2,6-sialyl-Sulfo-LN
glycan_dictionary_accession : GSD000002
glytoucan_accession : G41145LF
term_in_sentence : The alpha2-6-sialylated 6-sulfo-LacNAc determinant defined by the antibody was significantly expressed on a majority of normal human peripheral B-lymphocytes as well as follicular B-lymphocytes in peripheral lymph nodes.[PMID:17728258]
publication : 17728258
definition :
term_xref : GlycoMotif:GGM.000026|GTC:G41145LF
synonyms : 6-sialyl-6-sulfo LN
function : B-cell interaction with blood vessels and trafficking[PMID: 17728258]
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000003
term (main_entry) : 2-Fucosyl-GD1b
glycan_dictionary_accession : GSD000003
glytoucan_accession : G67383AR
term_in_sentence : They were fucosyl-Gv., fucoSyl-GDlb, and two uni que fucogangliosides having GMl or GOlb bas ic structure containing a substituent with the blood group B determinant. [PMID:3654655]
publication : 3654655
definition : (2S,4S,5R,6R)-5-Acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxyoxane-2-carboxylic acid.[CHEBI:156680]
term_xref : CHEBI:156680|GlycoMotif:GGM.000103|GTC:G67383AR
synonyms : 6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→8)-5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose|Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-8)NeuAc(a2-3)]Gal(b1-4)Glc
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000004
term (main_entry) : 2-Fucosyl-GM1
glycan_dictionary_accession : GSD000004
glytoucan_accession : G56526JU
term_in_sentence : These glycolipid products were identified as asialo-Gs.., GM h and fucosyl-Gq, by comparison with authentic glycolipid samples.[PMID:3654655]
publication : 3654655
definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-4-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:151476]
term_xref : KEGG:G12241|CHEBI:151476|CID:91849786|GlycoMotif:GGM.000101|GTC:G56526JU
synonyms : Fuc(a1-2)Gal(b1-3)GalNAc(b1-4)[NeuAc(a2-3)]Gal(b1-4)Glc|6-deoxy-alpha-L-galacto-hexopyranosyl-(1→2)-beta-D-galacto-hexopyranosyl-(1→3)-2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1→4)-[5-acetamido-3,5-dideoxy-D-glycero-alpha-D-galacto-non-2-ulopyranosylonic acid-(2→3)]-beta-D-galacto-hexopyranosyl-(1→4)-D-gluco-hexopyranose
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000005
term (main_entry) : 3-Sialyl-LN (type 2)
glycan_dictionary_accession : GSD000005
glytoucan_accession : G10203DW
term_in_sentence : Using new crystal structures, we also provide the atomic resolution basis for the differential recognition of 3′ and 6′SiaLacNAc1–4 (with the Galβ1–4 linkage known as Type 2 backbone16; Scheme 1) by TgMIC1-MARR, and make comparisons with the Type 1 chain isomer of 3′SiaLacNAc1–4 (designated 3′SiaLacNAc1–3).[PMID:19593815]
publication : 19593815|15659615|2414279|8586620|2111348|23747419
definition : A linear amino trisaccharide consisting of α-neuraminyl, β-D-galactosyl and N-acetyl-D-glucosamine residues linked in a (2→3) and (1→4) sequence.[CHEBI:52472]
term_xref : GTC:G10203DW|KEGG:G00253|SugarBind_Ligand:109|GlycoEpitope:EP0314|CHEBI:52472|GlycoMotif:GGM.000034
synonyms :
function :
disease_associations : Chronic gastritis[SugarBind_Ligand:109]|Toxoplasmosis[SugarBind_Ligand:109]|Peptic ulcers[SugarBind_Ligand:109]|Gastric cancer[SugarBind_Ligand:109]
wikipedia :
essentials_of_glycobiology :
GSD000006
term (main_entry) : 3'-Sulfo-Lewis a
glycan_dictionary_accession : GSD000006
glytoucan_accession : G78706CK
term_in_sentence : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:11504739]
publication : 11504739|17499486|17691854|12944557|19394320|7534477|11604107|28025252|9061363|9878545|11918697|24239607|28628803|25339106|21400496|17998215|12626387|11425799|12219077|10955596|9453593
definition : A branched amino trisaccharide consisting of N-acetylglucosamine having a fucosyl residue attached at the 4-position via an α-linkage and a 3-sulfated galactosyl residue attached at the 3-position via a β-linkage.[CHEBI:65149]
term_xref : GTC:G78706CK|GlycoEpitope:EP0009|CID:5289352|GlycoMotif:GGM.000030
synonyms : 3'-Sulfo-Lea|SuLe(a)|3'-sulpho-Le(a)|3-O-sulfo-Le(A)|3'-Sulfo Le^a|3'-Sulfo Lea|3'-Sulfo Lewis a
function : SO3-3-Gal and the SO3-3-Lea blood group antigen bound to H.pylori.[GlycoEpitope:EP0009]
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000007
term (main_entry) : 3'-Sulfo-Lewis x
glycan_dictionary_accession : GSD000007
glytoucan_accession : G12295TB
term_in_sentence : A remodeling system of the 3'-sulfo-Lewis a and 3'-sulfo-Lewis x epitopes.[PMID:11504739]
publication : 11504739|20695481|8688428|[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036 10536036]|12770775|11352731|9784103|9022803
definition : An amino trisaccharide that consists of N-acetyl-β-D-glucosamine having an α-L-fucosyl residue attached at position 3 and a 3-sulfated β-D-galactosyl residue attached at position 4; β-D-Galp3S-(1→4)-[α-L-Fucp-(1→3)]-D-GlcpNAc in which the configuration at the anomeric centre of the reducing-end residue is β. [CHEBI:65171]
term_xref : GTC:G12295TB|GlycoEpitope:EP0013|CID:5289353|CHEBI:65171|GlycoMotif:GGM.000029
synonyms : 3'-sulfo-Le(x)|3'-Sulfo Lewis x|3'-sulfo Le^x|3'-sulfo Lex
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000008
term (main_entry) : 6,6'-bisSulfo-Lewis x
glycan_dictionary_accession : GSD000008
glytoucan_accession : G00659GQ
term_in_sentence : Comparison of the reactivity pattern of HEV with the reactivity of the pure 6-sulfo, 6'-sulfo, or 6,6'-bissulfo sialyl Lewis X determinant with hitherto known anti-sialyl Lewis X antibodies strongly suggested 6-sulfo sialyl Lewis X to be the best candidate for the major sulfated sialyl Lewis X determinant on HEV, followed by 6,6'-bissulfo sialyl Lewis X, whereas 6'-sulfo sialyl Lewis X was unlikely. [PMID:9556613]
publication : 19756298|14593101|15175329|14568956|12163379|11919403|11520459|10728707|10200296|10528213|9712885| 9556613|9257857|9164959|9015359|8958810|7560094|7485559|7538131|8161542|7684905
definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-5-acetamido-6-hydroxy-2-(sulfooxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(sulfooxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid.[CHEBI:146095]
term_xref : GlycoEpitope:EP0016|CHEBI:146095|GlycoMotif:GGM.000028|GTC:G00659GQ
synonyms : 6,6'-DiSulfo Sialyl Lewis x|6,6-bisSulfo-Lewis x (6,60-bissulfo Lewis x )|6,6'- Disulfo Sialyl Lewis x|6,6'-bisSulfo-Lewis x|6,6'-bissulfo Lex|6,6'-Disulfo Sialyl Lewis x|6,6'-bissulfo Le^x
function : lymphocyte homing[GlycoEpitope:EP0016]
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000009
term (main_entry) : 6-Sialyl-GalNAc
glycan_dictionary_accession : GSD000009
glytoucan_accession : G08371CD
term_in_sentence : mmunohistochemical distributions of carbohydrate antigens based on the type 2 chain in normal as well as fetal and neoplastic tissues of human gastrointestinal tract were investigated with a monoclonal antibody (MAb) H11 (specific for type 2 chain) alone and in combination with the two MAbs MSG15 (for alpha 2----6 sialylated type 2 chain) and IB9 (for the alpha 2----6 sialylated type 2 chain and glycoproteins having NeuAc alpha 2----6Gal-NAc), and 188C1 (for short- and long-chain Lex antigens) and FH2 (for the long-chain Lex antigen). [PMID: 1618643]
publication : 1618643|6194157
definition : An amino disaccharide composed of N-acetylneuraminic acid and 2-(acetylamino)-2-deoxy-D-galactopyranose residues joined by an (α-2→6) glycosidic bond.[CHEBI:146820]
term_xref : GlycoEpitope:EP0352|KEGG:G00455|KEGG:G10625|CHEBI:146820|CID:11409652|GlycoMotif:GGM.000035|GTC:G08371CD
synonyms : Sialyl Tn antigen|6-Sialyl-GalNAc|6-Sialyl LN|6-Sialyl LN (type 1)|6-Sialyl LN (type 2)
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000010
term (main_entry) : 6-Sulfo LacNac
glycan_dictionary_accession : GSD000010
glytoucan_accession : G13157WZ
term_in_sentence : In the search for an additional marker to better dissect the two subsets we have explored the marker 6-sulfo LacNAc (slan).[PMID:31572354]
publication : 31572354|31191513|29977237|29900053|30984181|28732748|26510404|28769928|31154896|27541644|25262889|26155414|28499587|27086951|27315572|26162403|26391152|31730025|12354382|27318477|23879812|25340085|24682513|21377044|21098395|18942710|23559493|23890755|22643330|23460612|23402811|22890025|19589615|32939325|20210806|17616642|22907335|16782032|22188261|21283706|29875315|32413173|19546436|19384158|1429720|30519676
definition : An oligosaccharide sulfate that is N-acetyllactosamine in which the hydroxy group at position 6 of the N-acetylglucosamine ring has been converted into its hydrogen sulfate derivative.[CHEBI:148005]
term_xref : GlycoEpitope:EP0141|GTC:G13157WZ|CID:10322152|CHEBI:148005
synonyms : 6-Sulfo LacNAc
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000011
term (main_entry) : 6'-Sulfo Sialyl Lewis x
glycan_dictionary_accession : GSD000011
glytoucan_accession : G00672PE
term_in_sentence : Studies using sulfotransferase-deficient mice showed that 6-sulfo sialyl Lewis X (6-sulfo sLe(x)), a major ligand for L-selectin that is expressed on the high endothelial venules (HEVs), plays critical roles in lymphocyte homing to the peripheral lymph nodes.[PMID:2288521]
publication : 2288521|26137907|9400621|32744401|9556613|15972893|9015359|22691873|18652681|9722682|10435581|19458105|19359410|15228275|18250165|[https://pubmed.ncbi.nlm.nih.gov/10536036 10536036 10536036]|17944600|10460836|27993973|19149511|19150806|17172261|17142960|27956273|7578028|22260995|24519996|21596021|21982762|21775439|17334369|9710564|14593101|16227985|11895802|22750968|15157883|19067429
definition : A branched amino tetrasaccharide comprised of a trisaccharide chain of N-acetyl-α-neuraminic acid, 6-O-sulfo-β-D-glactose and N-acetyl-β-D-glucosamine residues linked sequentially (2→3) and (1→4), to the GlcNAC residue of which is also linked (1→3) an α-L-fucose residue.[CHEBI:71558]
term_xref : GlycoMotif:GGM.000025|GTC:G00672PE|CID:70698387|GlycoEpitope:EP0014|CHEBI:71558|SugarBind_Ligand:128
synonyms : 6'-sulfated sialyl Lewis x-|6'-sulfo-sLe(x)|Su-SaiLex|Su-Slex|6'-Sulfo-sialyl Lewis x
function : lymphocyte homing[GlycoEpitope:EP0014]
disease_associations : Influenza[SugarBind_Ligand:128]
wikipedia :
essentials_of_glycobiology : Chapter 14
GSD000012
term (main_entry) : 9-O-Acetyl GD3
glycan_dictionary_accession : GSD000012
glytoucan_accession : G74121RX
term_in_sentence : To determine whether 9-O-acetyl GD3 (acGD3) has a general antiapoptotic potential, the apoptosis-sensitive Jurkat cell line and an apoptosis-sensitive variant of the cell line Molt-4 were preincubated with micromolar concentrations of acGD3 and then treated with inducers of apoptosis.[PMID:16432837]
publication : 16432837|21507905|17512674|21930212|18194438|20739294|3216430|14724245|31373393|7558412|11273644|17385751|30694652|22894715|12973826|7859075|9749956|9874495|12486096|1989525|25330147|23478187|21807667|8486686|11465673|9511990|29270199|9268945|25045067|21618115|16434401|12493756|2302705|2198284|2685488|9328574|4055789|10096568|1644805|2582447
definition :
term_xref : GTC:G74121RX|GlycoEpitope:EP0064|CID:91852520|GlycoMotif:GGM.000093
synonyms : acGD3|9-O-Acetylated GD3|9-O-Acetyl-GD3|9-O-Ac-GD3|CD60b
function :
disease_associations : pancreas cancer[GlycoEpitope:EP0064]
wikipedia :
essentials_of_glycobiology :
GSD000013
term (main_entry) : 9-O-Acetyl sialic acid
glycan_dictionary_accession : GSD000013
glytoucan_accession : G47325QT
term_in_sentence : Levels of 9-O-acetyl sialic acid provide a distinct way to define progenitors and thus facilitate the study of hematopoietic differentiation.[PMID:31411667]
publication : 31411667|27936566|2509478|10049046|1826463
definition : N-acetyl-9-O-acetyl-alpha-neuraminic acid is a member of the class of N-acetylneuraminic acids that is alpha-neuraminic acid which has acetylated on N-5 and O-9. It has functional parent alpha-neuraminic acid.[CHEBI:84941]
term_xref : GTC:G47325QT|GlycoEpitope:EP0065|CID:13991612|CHEBI:84941
synonyms :
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 15
GSD000014
term (main_entry) : Blood group A (Type 2)
glycan_dictionary_accession : GSD000014
glytoucan_accession : G74353FF
term_in_sentence : One hybridoma antibody (AH16), obtained on immunization with human gastric cancer cell MKN45, was directed to the blood group A determinant carried by both type 1 and type 2 chains. [PMID:6583282]
publication : 27196314|6583282|8340255|18701592|21901093|2413709|8036794|1615929|3285099
definition : A branched amino tetrasaccharide comprising N-acetyl-β-D-glucosamine at the reducing end with a N-acetyl-α-D-galactosaminyl-(1→3)-[α-L-fucosyl-(1→2)]-β-D-galactosyl moiety attached at the 4-position.[CHEBI:62486]
term_xref : GTC:G74353FF|CID:53262376|GlycoEpitope:EP0257|CHEBI:62486|GlycoMotif:GGM.000038
synonyms : A Type 2|Blood group A type 2 chain
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 14
GSD000016
term (main_entry) : Alpha-gal antigen
glycan_dictionary_accession : GSD000016
glytoucan_accession : G24432YB
term_in_sentence : Therefore, alpha-gal antigen might be eliminated after a prolonged culture, when using human cells.[PMID:31267683]
publication : 31267683|29319188|29481481|26140655|30337555|29235434|22909134|28280265|7532618|23390540|22808845|29898796|22262104| 31267683|25430953|22993330|23578170|21043478|28294277|27696820|15814276|17991149|25577211|30578545|19895316|28068870|18546155|32907757|26485996|9771839|12042247|27567275|12131678|23114154|19184002|29577591|29806570|15638815|21118731
definition : A glycosylgalactose that consists of β-D-galactose having an α-D-galactosyl residue at the 3-position.[CHEBI:62330]
term_xref : GTC:G24432YB|GlycoMotif:GGM.000015|CID:52939789|CHEBI:62330
synonyms : a-Gal antigen
function : Has role as a carbohydrate allergen, epitope or an antigen.[CHEBI:62330]
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 14
GSD000017
term (main_entry) : Alpha-galactosylceramide
glycan_dictionary_accession : GSD000017
glytoucan_accession :
term_in_sentence : From 24 weeks of age, NZB/NZW F1 mice were injected with alpha-galactosylceramide (α-GalCer) or vehicle once a week for four weeks.[PMID:29844470]
publication : 29844470|30421497|31575643|30745361|30953000|30556652|29617191|31689579|28872688|30195979|29940370|27004737|27198610|28743554|31649670|31484693|25752588|21383248|25527277|30821985|28947140|31244823|29311431|30803854|29576533|26101952|31213291|22412194|28067024|31199716|27354638|24465013|25445911|28120096|15630427|27803187|21392534|31075434|22683545|26191196|26811064|23935988|28623127|24913977|25434827|23420533|21839133|25314062|27325450|23874157
definition :
term_xref :
synonyms : alpha-GalCer|alpha-GalCers|α-GalCer
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000018
term (main_entry) : Asialo-biantennary
glycan_dictionary_accession : GSD000018
glytoucan_accession :
term_in_sentence : Typical crystallizable fragment (Fc) glycans attached to the CH2 domain in therapeutic monoclonal antibodies (mAbs) are core-fucosylated and asialo-biantennary complex-type glycans, e.g., G2F (full galactosylation), G1aF (terminal galactosylation on the Man α1-6 arm), G1bF (terminal galactosylation on the Man α1-3 arm), and G0F (non-galactosylation).[PMID:30990348]
publication : 30990348|17645671|20959391|18615430|16945378|2065054|3084472|2386787 |22911097|24692304|17013932|7513972| 6626573|10835250|9684342
definition :
term_xref :
synonyms : asialo diantennary
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000019
term (main_entry) : Asialo-GM1
glycan_dictionary_accession : GSD000019
glytoucan_accession : G21856LC
term_in_sentence : We compared the lateral structure of giant unilamellar vesicles (GUVs) composed of three pseudo binary mixtures of different glycosphingolipid (GSL), i.e. sulfatide, asialo-GM1 or GM1, with POPC.[PMID:29106974]
publication : 29106974|3418980|26975993|8613364|9288228|26710925|24922516|6839313|1828259|2581667|8210226|25062498|9671150|10377092|6171919|3093429|6652964|3124753|8905612|18788941|1467432|8225593|2083955|6171918|7806377|1802483|7927723|9209156|21174147|2584393|12137200|6175621|2936802|8610366|21490162|1548508|3486908|26453755|7910939|3756909|1639356|3259967|2443562|3112077|2572647|25137483|2168971|6950172
definition :
term_xref : GlycoMotif:GGM.000099|GTC:G21856LC|CID:10169040|GlycoEpitope:EP0047|CHEBI:59216
synonyms : as-GM1|GA-1|Gangliotetraosylceramide|GgO4|Gg4|Asialo-GM1a|ganglio-N-tetraosylceramide
function :
disease_associations : Pleuropneumonia[SugarBind_Ligand:2]|Porcine fibrinohemorrhagic necrotizing pleuropneumonia[SugarBind_Ligand:2]|Actinomycosis[SugarBind_Ligand:2]|Lazy leukocyte syndrome[SugarBind_Ligand:2]|Pertussis[SugarBind_Ligand:2]|Cutaneous lesions[SugarBind_Ligand:2]|Melioidosis[SugarBind_Ligand:2]|Candidiasis[SugarBind_Ligand:2]|Taiwan acute respiratory agent[SugarBind_Ligand:2]|Trachoma[SugarBind_Ligand:2]|Cystitis[SugarBind_Ligand:2]|Chronic gastritis[SugarBind_Ligand:2]|Peptic ulcers[SugarBind_Ligand:2]|Gastric cancer[SugarBind_Ligand:2]|Klebsiella pneumonia infection[SugarBind_Ligand:2]|Pneumonia[SugarBind_Ligand:2]|Legionnaires' disease[SugarBind_Ligand:2]|Gonorrhea[SugarBind_Ligand:2]|Gastroenteritis[SugarBind_Ligand:2]|Toxoplasmosis[SugarBind_Ligand:2]|Plague[SugarBind_Ligand:2]|Diarrhea[SugarBind_Ligand:2]
wikipedia :
essentials_of_glycobiology :
GSD000020
term (main_entry) : B-GD1B
glycan_dictionary_accession : GSD000020
glytoucan_accession : G72557NR
term_in_sentence : The Molecular Modelling and 10 ns MD simulation of Botulinum Neuro Toxin/B-GD1A and BoNT/B-GD1B complex revealed that this toxin can interact with GD1A in the single binding mode and with GD1B in two binding modes.[PMID:22929125]
publication : 27956354|22929125
definition :
term_xref : GlycoMotif:GGM.000104|GTC:G72557NR|CID: 91847819|KEGG:G01803|CHEBI:153361
synonyms : B-GD1b
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000021
term (main_entry) : B-GM1
glycan_dictionary_accession : GSD000021
glytoucan_accession : G11485ID
term_in_sentence : The contribution of GM3 and GD3, which accounted for 95% of the ganglioside sialic acid at birth, decreased during the first 3 weeks of life. GM1, fucosyl-GM1, and B-GM1 were not detected at birth. [PMID: 3680254]
publication : 3680254
definition : (2S,4S,5R,6R)-5-Acetamido-2-[(2R,3S,4R,5R,6S)-3-[(2S,3R,4R,5R,6R)-3-acetamido-5-hydroxy-4-[(2R,3R,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-hydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid is a member of neuraminic acids.[CHEBI:147588]
term_xref : GlycoMotif:GGM.000102|GTC:G11485ID|CID:91853157|CHEBI:147588|SugarBind_Ligand:181
synonyms :
function :
disease_associations : Cholera[SugarBind_Ligand:181]
wikipedia :
essentials_of_glycobiology : Chapter 37
GSD000022
term (main_entry) : Biantennary
glycan_dictionary_accession : GSD000022
glytoucan_accession :
term_in_sentence : We found an efficient isopropylidenation reaction that selectively protects the terminal Gal-3,4-OH of a biantennary complex-type nonasaccharide isolated from a natural source.[PMID: 29249147]
publication : 29249147| 24991291|29409839| 30325416|18083109|26926155|16715395| 12634321|24211369|23115267|31907993| 23360551|20861009| 33142198|11442281|18687680|15680603|31888963| 14686925 [https://pubmed.ncbi.nlm.nih.gov/14686925 14686925]| 15819890| 22530754 [https://pubmed.ncbi.nlm.nih.gov/22530754 22530754]|22098756|9346821|19341309|18529007| 20580347|11784152|7773775|10913832|8547276|10463590|9404657|30525457|15316280|8068637|3881425| 6425277|8576139|29956878|1576211|11129583|30421263|8069634|30973186| 16704415| 21612260|29806066|29443078
definition : Type of N-linked glycan in which two antenna are present on the trimannosyl core, each initiated by GlcNAc additions catalyzed by position-specific N-acetylglucosaminyltransferases (GlcNAcTs). Each antenna can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [Essentials of Glycobiology:Glossary]
term_xref :
synonyms : diantennary
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 9
GSD000023
term (main_entry) : Biantennary complex
glycan_dictionary_accession : GSD000023
glytoucan_accession :
term_in_sentence : The crystal structure of Pterocarpus angolensis lectin is determined in its ligand-free state, in complex with the fucosylated biantennary complex type decasaccharide NA2F, and in complex with a series of smaller oligosaccharide constituents of NA2F.[PMID:16704415]
publication : 16704415|3731182|26747427| 32597008|6626573|29249147|28597152|25045879|30325416|12634321|31888963|26926155|23360551|33142198|9404657|29956878| 14686925|18687680|11784152|7773775|[https://pubmed.ncbi.nlm.nih.gov/22530754 22530754 22530754]|20580347|22098756|21612260|6425277|7691595|26780731|16285669|15819890|3924097|30448401|8547276|17049014|29408873
definition : A complex N-glycan that has two branches attached to the non-reducing terminal Man residues of the trimannosyl core. . Each branch is initiated with a GlcNAc and can be exteneded or capped with HexNAc, deoxyHex, Hex, or sialic acid residues. [CHEBI:156251]
term_xref : CHEBI:156251
synonyms : diantennary complex type
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000024
term (main_entry) : Bisecting GlcNac
glycan_dictionary_accession : GSD000024
glytoucan_accession :
term_in_sentence : The presence of a bisecting GlcNAc and the occurrence of alpha 2-6-linked Neu5Ac in the most abundant N-glycans, are new features for hCG-beta.[PMID:1374031]
publication : 1374031|29909448|29274553|32719771|22476631|31375533|26467158|27429195|20816221|26109616|30542567|30144245|25727145|29593568|32612952|9006930|19508951|16000695|32597008|19053837|22530754|30405631|19940114|32719549|9560299|29655002|10589784|29959030|20661133|9061364|31065629|20395209|29549127|30305426|29632412|24108122|24282611|27821068|14686925|10816579|25032906|30025558|9661906|8542600|31585439|29699572|27443163|30315103|23808883|18812317|19776078
definition : The bisecting GlcNAc is a modification of hybrid or complex N-linked glycans in which a single GlcNAc is added to the 3 position of the b-linked Man found in the trimannosyl core structure. The modification is catalyzed by beta 1,4-N-acetylglucosaminyltransferase III (GlcNAcT-III) or MGAT3 (E.C. 2.4.1.144). The addition of a bisecting GlcNAc on a hybrid or trimmed hybrid glycan prevents the subsequent action of N-glycan branching glycosyltransferases GlcNAcT-IV and GlcNAcT-V, but GlcNAcT3 can add a bisecting GlcNAc to the products of these enzymes. [PMID: 22476631]
term_xref : SID:163312364|KEGG:G13066
synonyms :
function : The bisecting GlcNAc of N-glycans regulates cellular signaling and tumor progression through modulating N-glycan/galectin interactions.[PMID: 22476631]Inhibits growth factor signaling and retards mammary tumor progression[PMID: 20395209]Integrin-mediated cell adhesion [PMID: 20816221]Important in fertilization and fetal development, neuritogenesis, immune tolerance, immunoglobulin G (IgG)[PMID: 32719771]
disease_associations : mammary tumor.[PMID: 20395209]
wikipedia :
essentials_of_glycobiology : Chapter 9
GSD000025
term (main_entry) : Bisialo-biantennary
glycan_dictionary_accession : GSD000025
glytoucan_accession :
term_in_sentence : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F, compared with elution positions of standard oligosaccharide structures, coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate, confirming earlier work published by this laboratory.
publication : 2386787|2065054
definition : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae.
term_xref :
synonyms : disialo biantennary|disialo diantennary|disialylated biantennary|disialylated diantennary
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000026
term (main_entry) : Bisialo-biantennary complex-type
glycan_dictionary_accession : GSD000026
glytoucan_accession :
term_in_sentence : Using anion-exchange liquid chromatography mapping of the oligosaccharide units cleaved from the proteins by glycopeptidase F , compared with elution positions of standard oligosaccharide structures , coupled with monosaccharide compositional analysis, we find that the human plasma protein contained only bisialo-biantennary complex-type carbohydrate and asialo-biantennary complex carbohydrate , confirming earlier work published by this laboratory.[PMID: 2386787]
publication : 2386787|26966183
definition : A binantennary glycan with sialic acid residues as non-reducing terminal residues on both antennae.
term_xref :
synonyms : Fully sialylated biantennary N-glycan
function :
disease_associations :
wikipedia :
essentials_of_glycobiology : Chapter 25
GSD000027
term (main_entry) : Blood group A (Type 2) - Lewis y
glycan_dictionary_accession : GSD000027
glytoucan_accession : G54826OZ
term_in_sentence : Monoclonal antibodies defining blood group A variants with difucosyl type 1 chain (ALeb) and difucosyl type 2 chain (ALey).[PMID:2417620]
publication : 2417620
definition : A branched amino pentasaccharide consisting of the linear trisaccharide N-acetyl-α-D-galactosaminyl-(1→3)-β-D-galactosyl-(1→4)-N-acetyl-β-D-glucosamine having α-L-fucosyl residues attached at position 2 of the galactose and position 3 of the glucosamine. Corresponds to a partial structure of blood group A type 2 oligosaccharide.[CHEBI:62990]
term_xref : GlycoEpitope:EP0261|GTC:G54826OZ|CHEBI:62990|CID:5289011|GlycoMotif:GGM.000039
synonyms : Blood group A (type 2) (A-Ley)|Blood Group A Type 2 (difucosyl)|Blood group A (type 2) (A-Lewis Y)|A-Ley|A-Le^y
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000028
term (main_entry) : Blood group A (Type 4)
glycan_dictionary_accession : GSD000028
glytoucan_accession : G37830TX
term_in_sentence : Moreover, we have found that αGal, but not αGalNAc, is a weak binder itself for DC-SIGN, which could endow an additional binding mode for the blood group B antigen, but not for blood group A.[PMID:31283166]
publication : 7800218|7521740|2458640|31283166
definition :
term_xref : GlycoMotif:GGM.000088|GTC:G37830TX|CID:91852258|KEGG:G00474|CHEBI:150159|SugarBind_Ligand:48
synonyms :
function :
disease_associations : Pyelonephritis[SugarBind_Ligand:48]|Acute cystitis[SugarBind_Ligand:48]
wikipedia :
essentials_of_glycobiology :
GSD000029
term (main_entry) : Blood group A trisaccharide
glycan_dictionary_accession : GSD000029
glytoucan_accession : G00066MO
term_in_sentence : A readily detectable carbohydrate in the urine of two siblings with neuronal ceroid lipofuscinosis was found to be the blood group A trisaccharide.[PMID:7249368]
publication : 19582848|7249368|8774717|2749874|28771597|30619340|2122121|11886841|2991755|12588002|3149698|7048329|7015594|10359132|8724140|1418679|1446307
definition : A branched amino trisaccharide consisting of β-D-galactose having an α-L-fucosyl residue at the 2-position and an N-acetyl-α-D-galactosaminyl residue at the 3-position.[CHEBI:61012]
term_xref : GlycoEpitope:EP0255|GTC:G00066MO|CID:49852448|KEGG:G10638|CHEBI:61012
synonyms : blood group A trisaccharide|blood group A type 1 trisaccharide
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :
GSD000030
term (main_entry) : Blood group A (Type 1)
glycan_dictionary_accession : GSD000030
glytoucan_accession : G66163TI
term_in_sentence : he basis of blood group A(1) and A(2) phenotypes has been debated for many decades, and still the chemical basis is unresolved. [PMID:19121199]
publication : 10942408|19121199
definition : An α-D-GalpNAc-(1→3)-[α-L-Fucp-(1→2)]-β-D-Galp-(1→3)-D-GlcpNAc having β-configuration at the reducing end anomeric centre.[CHEBI:62485]
term_xref : GlycoMotif:GGM.000044|GTC:G66163TI|GlycoEpitope:EP0256|CID:53262359|CHEBI:62485
synonyms : Blood group A(1)|blood group A antigen type 1
function :
disease_associations :
wikipedia :
essentials_of_glycobiology :